 
CONFIDENTIAL INFORMATION  CLINICAL STUDY PROTO COL  
 
An Open -label Study to Assess the Safety of Repeat Administration of FX006 to Patients with 
Osteoarthritis of the Knee   
 
PROTOCOL NUMBER:    FX006 -2016 -011  
 
PHASE:    3b  
 
STUDY MEDICATION (S): FX006  
 
INDICATION:    Osteoarthritis of the Knee    
  
MEDICAL MONITOR:   Robert D. Arbeit , MD  
 Chief Medical Officer  
 Flexion Therapeutics  
Tel: [PHONE_13499]  
  
SPONSOR:    Flexion Therapeutics   
           [ADDRESS_873426]   
                       Burlington, MA [ZIP_CODE]  
Tel: 781 -305-7777  
 
DATE:    16 October 2017   
  
VERSION:   2.0  
 
SUPERCEDES:   Version 1.0; [ADDRESS_873427]/Ethics committee  ................................ ............................ [ADDRESS_873428]:  FX006  ................................ ................................ 18 
5.2.2.  Rationale for FX006 in OA of the Knee  ................................ ................................ .....19 
5.2.3.  Non-clinical  ................................ ................................ ................................ ................ 19 
5.2.4.  Clinical Experience  ................................ ................................ ................................ .....19 
5.2.5.  Clinical Pharmacokinetics  ................................ ................................ .......................... 21 
5.2.6.  Clinical Pharmacodynamics  ................................ ................................ ....................... 21 
5.2.7.  Clinical Efficacy  ................................ ................................ ................................ ......... 21 
[IP_ADDRESS].  Study FX006 -2011 -001 ................................ ................................ .............................. 21 
[IP_ADDRESS].  Study FX006 -2014 -006 ................................ ................................ .............................. 22 
[IP_ADDRESS].  Study FX006 -2014 -008 ................................ ................................ .............................. 22 
5.2.8.  Clinical Safety  ................................ ................................ ................................ ............ 22 
5.2.9.  Conclusion  ................................ ................................ ................................ .................. 23 
6. THESE DATA PROVIDE B ASES FOR CONTINUED C LINICAL STUDY 
OF FX006. STUDY OBJECTIVES  ................................ ................................ ............ 24 
6.1. Primary Objective  ................................ ................................ ................................ .......24 
6.2. Exploratory Objective  ................................ ................................ ................................ .24 
7. INVESTIGATIONAL PLAN  ................................ ................................ ..................... 25 
7.1. Overall Study Design and Plan  ................................ ................................ ................... 25 
7.2. Site Staffing Requirements  ................................ ................................ ......................... 25 
7.3. Discussion of Study Design  ................................ ................................ ........................ 26 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 4 of 57 
 7.3.1.  Rationale for Study Population  ................................ ................................ ................... 26 
7.3.2.  Rationale for Dose Selection  ................................ ................................ ...................... 26 
7.3.3.  Rationale for Study Design  ................................ ................................ ......................... 26 
7.3.4.  Rationale for Study Parameters  ................................ ................................ .................. 26 
7.4. Selection of Study Population  ................................ ................................ .................... 27 
7.4.1.  Number of Patients  ................................ ................................ ................................ .....27 
7.4.2.  Screening Criteria  ................................ ................................ ................................ .......27 
[IP_ADDRESS].  Screening Inclusion Criteria  ................................ ................................ ....................... 27 
[IP_ADDRESS].  Screening Exclusion Criteria  ................................ ................................ ...................... 28 
7.4.3.  Repeat Administration Criteria  ................................ ................................ ................... 30 
[IP_ADDRESS].  Repeat Administration Inclusion Criteria  ................................ ................................ ...30 
[IP_ADDRESS].  Repeat Administration Exclusion Criteria  ................................ ................................ ..[ADDRESS_873429](s)  ................................ ................................ ......... 32 
7.5.3.  Receipt, Dispensing, and Storage  ................................ ................................ ............... 32 
7.5.4.  Packaging and Labeling of Study Medication  ................................ ............................ 32 
7.5.5.  Return of Study Medication  ................................ ................................ ........................ 32 
7.5.6.  Method of Assigning Patients to Treatment Groups  ................................ .................. 32 
7.5.7.  Blinding  ................................ ................................ ................................ ...................... 33 
7.5.8.  Intra -articular Injection Procedure  ................................ ................................ .............. 33 
7.5.9.  Treatment Compliance  ................................ ................................ ................................ 33 
7.6. Prior and Concomitant Therapy  ................................ ................................ .................. 33 
7.6.1.  Allowable Medications/Therapi[INVESTIGATOR_014]  ................................ ................................ .............. 33 
7.6.2.  Restricted Medications  ................................ ................................ ............................... 34 
7.7. Study Variables  ................................ ................................ ................................ ........... 34 
7.7.1.  Safety Variables  ................................ ................................ ................................ .......... 34 
7.7.2. Exploratory Efficacy Variables  ................................ ................................ .................. 34 
7.7.3.  Pharmacodynamic Variables  ................................ ................................ ...................... 34 
7.8. Schedule of Study Assessments ................................ ................................ .................. 35 
7.9. Study Procedures  ................................ ................................ ................................ ........ 37 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 5 of 57 
 [IP_ADDRESS].  Informed Consent  ................................ ................................ ................................ .......37 
7.9.2.  Review of Eligibility, Medical History, Prior Treatment, and Medications  .............. 37 
7.9.3.  Physical Examination  ................................ ................................ ................................ .37 
7.9.4.  Index Knee X -ray ................................ ................................ ................................ .......37 
7.9.5.  Index Knee Assessment  ................................ ................................ .............................. 38 
7.9.6.  12-lead ECG  ................................ ................................ ................................ ............... 38 
7.9.7.  Vital Signs  ................................ ................................ ................................ .................. 38 
7.9.8.  Height, Weight, and BMI determination  ................................ ................................ ....38 
7.9.9.  Central Clinical Laboratory Evaluations  ................................ ................................ ....39 
7.9.10.  Patient Questionnaires  ................................ ................................ ................................ 39 
7.9.11.  Daily Activity  ................................ ................................ ................................ ............. 39 
7.9.12.  Synovial Fluid Aspi[INVESTIGATOR_1516]  ................................ ................................ ........................... 40 
7.9.13.  Treatment Administration  ................................ ................................ ........................... 40 
7.9.14.  Review of Adverse Events and Concomitant Medications  ................................ ........ 40 
8. CLINICAL SAFETY ASSE SSMENTS  ................................ ................................ .....41 
8.1. Adverse Events  ................................ ................................ ................................ ........... 41 
8.1.1.  Definitions  ................................ ................................ ................................ .................. 41 
8.1.2.  Evaluating and Recording of Adverse Events  ................................ ............................ 42 
8.1.3.  Reporting of Serious Adverse Events  ................................ ................................ ......... 44 
8.1.4.  Safety Monitoring Roles  ................................ ................................ ............................. 44 
8.1.5.  Clinical Management of Index Knee -related Events  ................................ .................. 45 
8.1.6.  Pregnancy  ................................ ................................ ................................ ................... 45 
9. STATISTIC AL CONSIDERATIONS  ................................ ................................ .......46 
9.1. Statistical and Analytical Plans  ................................ ................................ .................. 46 
9.1.1.  Interim Analysis  ................................ ................................ ................................ .......... 46 
9.1.2.  Final Analyses  ................................ ................................ ................................ ............ 46 
9.2. General Considerations and Methods  ................................ ................................ ......... 46 
9.2.1.  Analysis Populations  ................................ ................................ ................................ ..47 
9.2.2.  Study Data  ................................ ................................ ................................ .................. 47 
[IP_ADDRESS].  Clinical Data – CDISC Study Data Tabulation Model (SDTM)  ................................ 47 
[IP_ADDRESS].  Analysis Data – CDISC Analysis Data Model (ADaM)  ................................ ............ 47 
9.2.3.  Study Variables for Assessment  ................................ ................................ ................. 47 
9.2.4.  Sub-Groups and Covariates  ................................ ................................ ........................ 47 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 6 of 57 
 9.3. Determination of Sample Size  ................................ ................................ .................... 48 
9.4. General statistical Methods  ................................ ................................ ......................... 48 
9.4.1.  Demographics and Baseline Characteristics  ................................ ............................... 48 
9.4.2.  Exposure  ................................ ................................ ................................ ..................... 48 
9.4.3.  Exploratory Efficacy Analyses  ................................ ................................ ................... 48 
9.4.4.  Safety Analyses  ................................ ................................ ................................ .......... 49 
10. DATA QUALITY ASSURAN CE ................................ ................................ .............. 50 
11. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]  ................................ ....................... 51 
11.1.  Case Report Forms  ................................ ................................ ................................ .....51 
11.2.  Study Medication Accountability  ................................ ................................ ............... 51 
11.3.  Confidentiality of Data  ................................ ................................ ............................... 51 
11.4.  Retention of Records  ................................ ................................ ................................ ..51 
11.5.  Protocol Adherence  ................................ ................................ ................................ ....52 
12. PUBLICATION POLICY  ................................ ................................ .......................... 53 
12.1.  Sponsor’s Publication Policy  ................................ ................................ ...................... [ADDRESS_873430] OF TABLES  
Table 1:  Schedule of Study Assessments ................................ ................................ .................. 36 
Table 2:  BMI Calculations  ................................ ................................ ................................ ........ 38 
Table 3:  Clinical Laboratory Panel  ................................ ................................ ........................... 39 
 
 
 
  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 7 of 57 
 1. ABBREVIATIONS AND DE FINITION OF TERMS  
ACR  American College of Rheumatology  
ADL  Activities of daily living  
ADaM  Analysis Data Model  
ADP  average daily pain  
ADRG  Analysis Data Reviewer’s Guide  
AE adverse event  
ANOVA  analysis of variance  
AUC  area under the concentration -time curve  
BMI  Body Mass Index  
CDISC  Clinical Data Interchange Standards Consortium  
CFR  Code of Federal Regulations  
CGIC  Clinical Global Impression of Change  
CI confidence interval  
CMC  Carboxymethylcellulose sodium  
CTCAE  Common Terminology Criteria for AEs  
CSR  Clinical  Study Report  
CV coefficient of variation  
ECG  Electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture  
EULAR  European League Against Rheumatism  
GCP  Good Clinical Practice  
GPAQ  Global Physical Activity Questionnaire  
HIV Human Immunodeficiency Virus  
HPA  hypothalamic -pi[INVESTIGATOR_2117] -adrenal  
IA intra-articular  
IB Investigator’s Brochure  
IRB/EC  Institutional Review Board/Ethics Committee  
IM intramuscular  
IV intravenous  
K-L Kellgren -Lawrence  
KM Kaplan -Meier  
KOOS  Knee injury and Osteoarthritis Outcome Score  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  mixed model for repeated measures  
NaCl  sodium chloride  
OA osteoarthritis  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 8 of 57 
 OARSI  Osteoarthritis Research Society International  
PGIC  Patients’ Global Impression of Change  
PLGA  poly[lactic -co-glycolic acid]  
PK pharmacokinetic  
PRP platelet rich plasma  
PTOA  post-traumatic osteoarthritis  
QOL  Quality of Life  
QTc QT interval corrected for heart rate  
RBC  red blood cells  
SAE  serious adverse event  
SAP statistical analysis plan  
SDRG  Study Data Reviewer’s Guide  
SDTM  Study Data Tabulation Model  
TEAE  treatment -emergent adverse event  
TA1 triamcinolone acetonide  
TAcs2 triamcinolone acetonide injectable suspension, immediate -release 
(commercially available)  
US [LOCATION_002]  
USP [LOCATION_002] Pharmacopeia  
w/w weight/weight  
WBC  white blood cells  
WOMAC  Western Ontario and McMaster Universities Osteoarthritis Index  
                                                 
[ADDRESS_873431] protocols and documents as TCA -IR 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 9 of 57 
 2. SYNOPSIS  
Title of Study: An Open -label Study to Assess the Safety of Repeat Administration of FX006 to Patients with 
Osteoarthritis of the Knee  
Study Centers:   Approximately 20 centers  
Study Phase:   3b 
Objectives : 
The primary objective of this study is to assess the overall safety and general tolerability of repeat administration of 
FX006 (two doses of 32 mg FX006) in patients with symptomatic osteoarthritis (OA) of the knee.  
Exploratory objectives of this study include the following:  
 examine efficacy signals for sustained pain reduction following two doses of 32 mg FX006.  
 collect synovial fluid samples to enable  potential  future examination of  synovial fluid biomarkers that may 
contribute to the pathogenesis of OA and/or be associated with responsiveness to FX006 treatment.  
Study Design and Methodology : 
This study is an open -label, repeat administration design of 32 mg FX006. The study will be  conducted in male and 
female patients ≥ [ADDRESS_873432] initial injection 
at: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, [ADDRESS_873433] initial injection 
at: Weeks 4, 8, 12. 
Patients who are not eligible for a second injection of FX006 after evaluation at Weeks 12, 16, 20, and [ADDRESS_873434] 
initial injection at: Week s 4, 8, 12, 16, 20 , and 24.   
Refer to  Appendix  2 Study Visit Flow Chart . 
The study is expected to enroll over approximately 6 months.  
Number of Patients : 
Approximately [ADDRESS_873435], Dose and Mode of Administration : 
FX006 – extended release formulation of TA in 75:25 poly(lactic -co-glycolic) acid (PLGA) microspheres . 
Nominal 32 mg TA, IA, administered as a  single  5 mL injection  
Reference Compound(s), Dose and Mode of Administration : 
Not applicable  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 10 of 57 
 Duration of Dosing : 
Single IA injection for all enrolled patients  at Day 1/Baseline , and a second IA injection for those meeting repeat 
administration  requirements at either Week 12, 16, 20 , or 24.  
Screening Inclusion Criteria :  
To be included in the trial, patients must fulfill the following criteria  to participate in the study  
1. Written consent to participate in the study  
2. Willingness and ability to comply with the stud y procedures and visit schedules and ability to follow verbal 
and written instructions  
3. Male or female 40 years of age  
4. Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening (patient  self-report is 
acceptable)   
5. Currently meets ACR  Criteria (clinical and radiological) for OA ( Altman et al, 1986 ) as follows:  
 Knee pain  
 at least 1 of the following:  
o Age > 50 years  
o Stiffness < 30 minutes  
o Crepi[INVESTIGATOR_72831]  
 Osteophytes  
6. Kellgren -Lawrence (KL) Grade 2, 3 or 4 in the index knee based on X -ray performed during Screening 
(locally read)  
7. WOMAC A total sum score of ≥ 6 at Screening and Day 1/Baseline  
8. Index knee pain for >[ADDRESS_873436] month (as reported by [CONTACT_102])  
9. If bilateral OA exists, pain in the co ntralateral knee must be less than pain in the index knee as reported by 
[CONTACT_102]  
10. Body mass index (BMI) ≤ 40 kg/m2s 
11. Ambulatory and in good general health  
12. Willingness to abstain from use of the following protocol -restricted medications during the study:  
 Intravenous (IV), intramuscular (IM) and oral corticosteroids (Note: inhaled, intranasal and topi[INVESTIGATOR_88896])  
 IA corticosteroids in any joint  
 IA viscosupplementation (hyaluronic acid) or any IA intervention (IA injection, IA aspi[INVESTIGATOR_1516] , etc.) in 
the index knee  
 Opi[INVESTIGATOR_858]  
 Any investigational drug, device or biologic  
 Immunomodulators, immunosuppressives, or chemotherapeutic agents  
 Live or live attenuated vaccines  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 11 of 57 
 Screening Exclusion Criteria : 
Patients fulfilling at least one of the following criteria may not be included in the study:  
Disease -related criteria  
1. Reactive arthritis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or arthritis associated 
with inflammatory bowel disease  
2. History of infection in the index knee joint  
3. Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of 
Screening  
4. Presence of surgical hardware or other foreign body in the index knee  
5. Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months of Screening  
Previous or concomitant treatment -related criteria  
6. IA corticosteroid (investigational or marketed) in index knee within 3 months of Screening  
7. IA hyaluronic acid (investigational or marketed) in the index kn ee within 6 months of Screening  
8. IV or IM corticosteroids (investigational or marketed) within 3 months of Screening  
9. Oral corticosteroids (investigational or marketed) within 1 month of Screening  
10. Any other IA drug/biologic use within 6 months of Screening o r 5 half -lives (whichever is longer) (e.g.,  
platelet rich plasma (PRP) injection, stem cells, prolothera py and amniotic fluid injection)  
11. Prior administration of FX006  
12. Prior arthroscopic or open surgery of the index knee within 12 months of Screening  
13. Planned/anticipated surgery of the index knee during the study period  
Patient -related criteria  
14. Known hypersensitivity to any form of triamcinolone  
15. History of sarcoidosis or amyloidosis  
16. Active or history of malignancy within the last 5 years, with the exce ption of resected basal cell carcinoma, 
squamous cell carcinoma of the skin, or effectively managed cervical carcinoma  
17. Known active or quiescent systemic fungal, bacterial, mycobacterial (including tuberculosis), viral or 
parasitic infections, or, shingles , herpes zoster and ocular herpes simplex  
18. Any infection requiring IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of 
Screening  
19. History of osteomyelitis  
20. Known or clinically suspected infection with human immunodeficiency virus  (HIV), hepatitis B or C 
viruses  
21. Any clinically significant electrocardiogram (ECG) abnormality as judged by [CONTACT_737]  
22. Patients requiring or likely to require chronic treatment with corticosteroids during the study period based 
on patient medical hi story  
23. History of , or active Cushing’s syndrome  
24. Active substance abuse (drugs or alcohol), history of chronic substance abuse within the past year, or prior 
chronic substance abuse judged by [CONTACT_651343]  
25. Skin breakdown at the knee where the injection would take place  
26. Women who are pregnant or nursing or plan to become pregnant during the study; men who plan to 
conceive during the study  
27. Women of child -bearing potential (not surgically sterile or post -menopausal for at least 1 year as 
documented in medical history) not using a highly effective method of contraception [abstinence; oral, 
injected or implanted hormonal methods of contraception; intrauterine device or intrauterine system; 
condom or occlusive cap (diap hragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository; or male sterilization (vasectomy)]  
 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 12 of 57 
 28. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 5 years of Screening  
29. Has received a live or live attenuated  vaccine within 3 months of Screening  
30. Use of any other investigational drug or device within 30 days of Screening or within 5 half -lives 
(whichever is longer) or an investigational biologic within 60 days of Screening or within 5 half -lives 
(whichever is l onger)  
31. Any other clinically significant acute or chronic medical conditions (e.g., bleeding disorder) that, in the 
judgment of the Investigator, would preclude the use of an IA corticosteroid or that could compromise 
patient safety, limit the patient’s abi lity to complete the study, and/or compromise the objectives of the 
study  
Repeat Administration Inclusion Criteria:   
To be eligible to receive a repeat administration, patients must fulfill the following criteria:  
1. Benefit from the initial dose of FX006 in the opi[INVESTIGATOR_651321]  
2. No major safety concerns during the initial dose period as assessed by [CONTACT_737]  
3. Clinically indicated to receive a second dose of FX006 in the opi[INVESTIGATOR_651322]  
4. WOMAC A total sum score of ≥ [ADDRESS_873437] Week 12 and the willingness and 
ability to continue to co mply through Week 52  
6. Willingness to abstain from use of protocol -restricted medications during the study   
Repeat Administration Exclusion Criteria:   
Patients fulfilling at least one of the following  are not eligible to receive a repeat administration:  
1. Clinical signs and symptoms of active knee infection or crystal disease of the index knee  
2. Received a non -protocol specified IA intervention (IA injection, IA aspi[INVESTIGATOR_1516], etc.) in index knee during 
study participation  
3. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents during study participation  
4. Received a live or attenuated vaccine during study participation  
5. Use of any other investigational drug, device or biologic during study participation  
6. Allergic reaction to initial dos e of [ADDRESS_873438]  
9. Women who are pregnant or nursing or plan to become pregnant d uring the study; men who plan to 
conceive during the study  
10. Women of child -bearing potential (not surgically sterile or post -menopausal for at least 1 year as 
documented in medical history) not using a highly effective method of contraception [abstinence; o ral, 
injected or implanted hormonal methods of contraception; intrauterine device or intrauterine system; 
condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal 
foam/gel/film/cream/suppository; or male sterilization (vasectomy)]  
11. Any ot her clinically significant acute or chronic medical conditions (e.g., bleeding disorder) that, in the 
judgment of the Investigator, would preclude the use of an IA corticosteroid or that could compromise 
patient safety, limit the patient’s ability to compl ete the study, and/or compromise the objectives of the 
study  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 13 of 57 
 Procedures and Assessments : 
The study will involve a Screening period ( a minimum of 7 days, up to 21 days), dosing at Day 1/Baseline and up to 
13 additional outpatient visits (Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 , and 52) depending if the patient is 
eligible for and receives a second injection.    
At specified times throughout the study, patients will undergo physical examinations, index knee assessments and 
index knee X -rays; blo od samples will be collected for laboratory safety tests and vital signs will be collected or 
measured.  Information regarding AEs and concomitant medications will be collected.  
Patients will have index knee synovial fluid collected at baseline and the week at which the second dose is 
administered (if the patient is eligible to receive a second dose) .  Patients that are not eligible to receive a second 
dose will not have synovial fluid drawn at their final study visit.  These samples  will be preserved fo r potential 
future OA biomarker analyses.  
Steps per day will be captured using a measured function device.  Patients will be provided with a device at the 
Screening visit to be worn for at least 7 days prior to Baseline/Day 1 through Week 12. The site will  confirm patient 
compliance with wearing the device to capture steps per day data at each patient visit from Day 1 through Week 12.  
As well, patients will complete the Global Physical Activity Questionnaire (GPAQ) at Screening  and at Week 12 . 
During out -patient visits, patients will complete the Western Ontario and McMaster Universities (WOMAC®) 
Osteoarthritis Index Likert (LK) 3.1 and the Knee injury and Osteoarthritis Outcome Score (KOOS) Quality of Life 
(QOL) Subscale . 
Blinding :  
This is an open -label study.  
IP Administration  Procedure :  
IA injections will be performed by [CONTACT_538726].  The injector may choose the position of the knee (e.g., 
extended or flexed), the approach for the injection (e.g., medial or lateral) and the numbing agent to be used (e.g., 
ethyl chloride, subcuta neous lidocaine; IA anesthetics are not allowed) based on standard of care. Sterile technique 
should be used.   
Prior to injection, the index knee should be thoroughly cleansed using a bactericidal solution.  The index knee will 
be aspi[INVESTIGATOR_651323] p rior to administration of study medication.  Following attempted aspi[INVESTIGATOR_1516], [ADDRESS_873439] to physical activity throughout 
the duration of the study.  
In the event that the patient has an immediate reaction (e.g., tenderness, increased pain, swelling, effusion, 
decreased mobility of the index knee), the patient should be treated according to local clinical guidelines and 
physician experience  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 14 of 57 
 Concomitant Medications:  
The exclusion criteria indicate that a patient may not be enrolled if he/she has used any of the following within the 
specified windows.  In addition these medications should not be taken or used throughout the study:   
 IV, IM or oral corticos teroids  
 IA corticosteroids in any joint  
 IA viscosupplementation (hyaluronic acid) or any IA intervention (IA injection, IA aspi[INVESTIGATOR_1516], etc.) in the 
index knee  
 Opi[INVESTIGATOR_858]  
 Any investigational drug, device or biologic  
 Immunomodulators, immunosuppressives, or ch emotherapeutic agents  
 Live or live attenuated vaccines  
Criteria for Evaluation:  
Safety  Variables  
Safety and tolerability will be evaluated on the basis of AEs spontaneously reported by [CONTACT_569535]: physical examinations, index knee assessments, vital 
signs, and clinical laboratory evaluations.  In addition the index knee will be evaluated by X -ray and assessed by a 
central imaging vendor for joint space narrowing, chondrolysis, subchondral bone changes, bone infarcts, avascular 
necrosis, joint swelling , and insufficiency fracture.  
Exploratory Efficacy  Variables  
 Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index (Likert (LK) 3.1, 5 -point 
scale): pain, stiffnes s and function domains independently and collectively ( Bellamy et al, 1988 ).  
 Knee injury and Osteoarthritis Outcome Score (KOOS) Quality of Life (QOL) Subscale  
 Daily activity measured as steps per day  
 Global Physi cal Activity Questionnaire (GPAQ) domains for Occupational physical activity, Transport -
related physical activity, and Physical activity during discretionary or leisure time)   
Sample Size Considerations:  
A sample size of approximately [ADDRESS_873440] 100 
patients who receive two doses of 32 mg FX006 are enrolled and followed for 52 weeks, approximately 200 patients 
will be enrolled based on an estimate that approximately 66% of patients enrolled will be eligible to receive a 
second dose of 32 mg FX006 and approximately 75% of subjects who receive a second dose will complete the study 
through Week 52.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 15 of 57 
 Statistical Methods:  
A comprehensive statistical analysis plan (SAP) will be written and approved prior to database lock for this study  
that describes the final analyses to be completed for safety and exploratory efficacy endpoints.  
No formal interim analysis is planned for  the primary safety endpoints in  this open -label study to assess the safety 
and tolerability of FX006 after repeat administration .  However, i nterim analysis  may be conducted  with exploratory 
endpoints to examine efficacy signals f ollowing administration of one or two doses of 32mg FX006 . These interim 
analyses on exploratory endpoints may be completed for  data review , regulatory updates , and/or publication (or 
presentation at congresses) for this open -label study. Any interim analysis completed will have an interim analysis 
plan written and approved to describe the purpose and analytical objectives of the interim analysi s.  Final analyses , 
described in the protocol and statistical analysis plan,  will be conducted after completion of the study, when all 
subjects have either discontinued the study early (prior to Week 52) or completed the study through Week 52.  
Demographic and baseline characteristics will be listed by [CONTACT_569552], and will be summarized by 
[CONTACT_3148].  Frequencies and proportions will be presented for the categorical variables and descriptive statistics will 
be presented for continuous variables.  
Treatment exposure will be listed by [CONTACT_569552], and will be summarized by [CONTACT_10566].  
The examination of efficacy is exploratory in this study. Data from the WOMAC® questionnaire will be presented in 
by-patient listings with summary pr esentation of the data and exploratory analyses.  
Analysis of the magnitude of pain relief observed with WOMAC A (pain), stiffness (WOMAC B), and function 
(WOMAC C) will be explored between patients who receive one dose and those receiving a second followi ng the 
first and second doses of 32 mg FX006 will be explored with a mixed model for repeated measures (MMRM) with 
fixed effects of number of doses (1 or 2) received, and a dose by [CONTACT_6491]. Model covariates will include 
study site, and potentially  other variables.  Subject will be a random effect in the model.  Time points of interest for 
this analysis are those when a subject is eligible for a second dose.  
A second within subject analysis will be completed for subjects who receive two doses of FX0 [ADDRESS_873441] after receiving the second dose: WOMAC after the first dose, 
compared to WOMAC following the second dose. The change from baseline to the last WOMAC score for the first 
dose will be compared to  the change from the last score prior to the second dose to the last WOMAC score following 
the second dose. The increment difference in the overall change for the first dose compared to second dose will be 
explored with a linear model.  
Evaluation of dose -response will be assessed descriptively with an examination of WOMAC A responses at the time 
(in weeks) of second dose administration to assess the magnitude of scores at each week that a second dose may be 
administered. The time to maximal pain relief resp onse with WOMAC A following the first and second doses of 
32 mg FX006 will be examined using a Kaplan -Meier (KM) procedure.  
Questionnaire data from the Global Physical Activity Questionnaire (GPAQ) domains (occupational physical 
activity, transport -related  physical activity, and physical activity during discretionary or leisure time) will be 
described descriptively at the two time points collected ( Screening and Week 12 ). The change in GPAQ domain 
scores and total score will be examined with an analysis of variance (ANOVA) model with summaries comparing 
patients who receive one dose to those receiving two doses of 32 mg FX006. GPAQ information collected at 
Screening will be utilized to normalize steps per day based on lifestyles activity.  GPAQ information w ill be a model 
covariate in subsequent analyses.  
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) dictionary.  Incidences 
(number and percent) of treatment -emergent adverse events (TEAEs), those events that started after do sing or 
worsened in severity after dosing, will be presented by [CONTACT_1570].  Incidences of TEAEs will also be presented 
by [CONTACT_218764].  
Similar presentations will be provided for serious AEs, AEs leading to wi thdrawal from the study, or AEs leading to 
death. Analysis of AE data will include examination of the incidence rates of TEAEs and index knee related TEAEs 
following the first dose and second dose, as well as the cumulative incidence of TEAEs after all dos es of 32 mg 
FX006. Both the number of events and the number of patients experiencing an event will be examined to assess the 
by [CONTACT_651344] . 
Clinical laboratory data and vital sign information  will be presented as descriptive summary statistics for value and 
change from Baseline at each individual time point.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 16 of 57 
 3. ETHICS  
The study will be conducted according to the Declaration of Helsinki, Protection of Human 
Volunteers (21 CFR 50), Institutional Review Boards (21 CFR 56), and Obligations of Clinical 
Investigators (21 CFR 312).  
3.1. Institutional Review Board /Ethics committee   
This study will be conducted in compliance with current Good Clinical Practices (GCP) and 
Title  21 Part 56 of the [LOCATION_002] of America Code of Federal Regulations (CFR) relating to 
Institutional Review Board (IRB)/Ethics Committee (EC).  
This study protocol and other related study documents will be submitted to the IRB/EC by [CONTACT_651345].  IRB/EC approval 
must be obtained before commencement of any study procedures. The study will be conducted 
only at sites where IRB/IEC approval has been obtained.  
3.2. Ethical Conduct of Study  
This study will be conducted in accordan ce with the protocol, GCP guidelines and applicable 
national regulatory requirements.  
GCP is an international ethical and scientific quality standard for designing, conducting, 
recording, and reporting studies that involve the participation of human patien ts. Compliance 
with this standard provides public assurance that the rights, safety, and well -being of study 
patients are protected, consistent with the principles that have originated in the Declaration of 
Helsinki and that the clinical study data are cre dible.  
3.3. Patient  Information and Consent  
Prior to initiation of any study -related procedures, patients will give their written consent to 
participate in the study after having been informed about the nature and purpose of the study, 
conditions  of participati on and termination , and risks and benefits.  
An IRB/EC -approved informed consent document must be signed by [CONTACT_12718]’s 
legal guardian before his or her participation in the study.  A copy of the informed consent 
document must be provided t o the patient or the patient’s legal guardian.  If applicable, it will be 
provided in a certified translation of the local language.  
Signed informed consent forms must remain in each patient’s study file and must be available for 
verification by [CONTACT_651346].  
Flexion Therapeutics, Inc . Protocol FX006 -[ADDRESS_873442] 
research organizations.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 18 of 57 
 5. INTRODUCTION  
5.1. Osteoarthritis  
Osteoarthritis (OA) is a painful and debilitating musculoskeletal disease that is characterized by 
[CONTACT_90169]-articular ( IA) inflammation, deterioration of articular cartilage, and degenerative changes to 
peri-articular and subchondral bone (Creamer and Hochberg, 1997; Goldring and Goldring, 
2006 ).  Arthritis is the most common cause of disability in the [LOCATION_002] (US) and OA is the 
most common joint disease, affecting [ADDRESS_873443] that OA accounts for over $[ADDRESS_873444] large 
weight -bearing joints like the knees and hips, but also occurs in the shoulde rs, hands, feet and 
spi[INVESTIGATOR_050].  Patients with OA suffer from joint pain, tenderness, stiffness and limited movement.  As 
the disease progresses, it becomes increasingly painful and debilitating, culminating, in many 
cases, in the need for total joint arthropla sty. 
Current Guidelines from the American College of Rheumatology (ACR), Osteoarthritis Research 
Society International (OARSI) and the European League against Rheumatism (EULAR) 
recommend the use of IA corticosteroids for short -term acute pain relief ( ACR Subcommittee 
2000; Hochberg et al, 2012; Jordan et al, 2003 ). 
While historically OA has been considered a non -inflammatory disease, it is increasingly being 
recognized that chronic synovitis occurs in all stages of knee OA ( Benito et al, 2005 ; Sellam and 
Berenbaum, 2010; Wenham and Conaghan, 2010 ).  As synovial inflammation is correlated with 
clinical symptoms and joint degeneration, it should be an important target for therapeutic 
intervention.  The inflamed synovium may well be the target for IA corticosteroids which are 
widely used in knee OA ( Ayral et al, 2005 ). 
5.2. Background  
5.2.1.  Investigational Me dicinal Product:  FX006  
FX006 is an extended -release formulation of triamcinolone acetonide (TA) for IA  administration 
that is being developed for the treatment of patients with  pain attributed to  OA of the knee.  
FX006 is intended to deliver TA to the syn ovial and peri -synovial tissues for a period of 
approximately 3 months depending on the dose administered (Bodick et al, 2013 ). 
FX006 contains TA, [LOCATION_002] Pharmacopeia  (Ph. Eur/USP), formulated in 75:25 
poly(lactic -co-glycolic acid) (PLGA) microspheres with a nominal drug load of 25% (w/w) and 
is provided as a sterile white  to off -white powder for reconstitution. The drug product is 
reconstituted with diluent containing an isotonic, sterile aqueous solution of sodium ch loride 
(NaCl; 0.9% w/w), carboxymethylcellulose sodium (CMC; 0.5% w/w) and polysorbate -80 (0.1% 
w/w) to form a suspension prior to IA injection.   
Further details of the physiochemical properties of FX006 can be found in the Investigator’s 
Brochure (IB).  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 19 of 57 
 5.2.2.  Rationale for FX006 in OA of the Knee  
Available clinical and nonclinical data indicate that FX006 is likely to be safe and well tolerated 
and has the potential to provide pain relief that is meaningfully better and more persistent than 
that provided by [CONTACT_651347] ( TAcs ).  Nonclinical data and the 
literature suggest that this potential could extend to limiting structural progression in patients 
with inflammatory joint disorders. The near term clinical development program for FX 006 
focuses on the analgesic effects in patients with OA of the knee.  
5.2.3.  Non-clinical   
The safety of FX006 was evaluated following single IA injection in one non -GLP rat toxicity 
study and two GLP -compliant dog toxicity studies, and following repeated IA inje ction in one 
GLP -compliant dog toxicity study.  In the repeat dose study, dogs were dosed once every 3 
months (1Q3M) for a total of 3 doses, or once every month (1Q1M) for a total of 3 doses); local 
and systemic (steroid target tissues) toxicity were asses sed. 
The systemic effects of repeat IA administration of FX006 containing up to 18.75  mg of TA and 
75 mg of PLGA microspheres were consistent with known TA/corticosteroid affects and were 
similar for the 1Q3M and 1Q1M dose regimens.  Regarding local toxici ty, at [ADDRESS_873445] dose following I.A. administration every 3 months (1Q3M), the only effect on cartilage 
observed at [ADDRESS_873446] -dose, ther e were additional changes in the structure and 
cellularity of articular cartilage in both the TAcs  and FX006 groups (in males only).  These 
effects are consistent with the known effects of corticosteroids in normal joints.  Occasional 
FX006 -treated animals  show slower recovery for cartilage changes compared to TAcs -treated 
animals, as expected based on the longer exposure to TA in the joints of these animals.  After 
monthly dosing (Q1M), small changes in structure and cellularity were present at [ADDRESS_873447] dosing.  An increased incidence 
and/or intensity of lymphocyte and plasma cells, and minimal fibrosis were also observed in the 
blank microsphere and FX006 groups at [ADDRESS_873448] tissue response, which is an expected reaction to PLGA products and is consistent 
with a foreign body response.  
Additional details on  non-clinical pharmacology, pharmacokinetics (PK) and ph armacodynamics 
in animals and toxicology information for TA, PLGA , and FX006 can be found in Section 4 of 
the IB.  
5.2.4.  Clinical  Experience  
The clinical development of FX006 to date consists of eight completed studies (FX006 -2011 
001, FX006 -2011 -002, FX006 -2013 -005, FX006 -2014 -006, FX006 -2014 -007, FX006 -2014 -008, 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 20 of 57 
 FX006 -2015 -009 and FX006 -2015 -010) conducted in patients with pain associated with OA of 
the knee. A brief summary of each study and data from the completed and fully analyzed studies 
is presented below.  
NOTE TO REVIEWER :  Subsequent to completion of the human pharmacology, efficacy , and 
safety studies reported herein (as of September 2017), extensive in -house testing was performed 
to assess the actual FX006 dose removed and delivered under the conditions  of the dose 
preparation procedure.  This in -house testing determined that the FX006 delivered dose to the 
patient from an FX006 [ADDRESS_873449] clinical studies using a FX006 40 mg 
dose under the current resuspension conditions (5 mL of diluent) should be considered to have 
delivered a 32 mg dose of TA.  All future studies performed with FX006 from the date of 
Investigator’s Brochure Version 7.[ADDRESS_873450] a 32 mg dose.  
Completed studies  
Study FX006 -2011 -001 was a Phase 2b, mul ti-center, randomized, double -blind, dose -ranging, 
active comparator study.  The primary objectives of this study were to assess the magnitude and 
duration of pain relief of a single 3 mL IA injection of FX006 ( 10, 40, or 60 mg) relative to 
40 mg of TAcs  and assess the general tolerability of FX006.   
Study FX006 -2011 -002 was a Phase 2, double -blind, randomized, parallel -group, active 
comparator study.  The primary objectives of this study were to assess the safety and tolerability 
of a single 3 mL IA injec tion of FX006 (10, 40 , or 60 mg), characterize the systemic PK profile 
of TA from FX006 relative to 40 mg of TAcs , and characterize the effects on the hypothalamic -
pi[INVESTIGATOR_2117] -adrenal (HPA) axis of FX006 relative to 40 mg of TAcs .   
Study FX006 -2013 -005 was a Phase 2, open -label, single administration study.  The objectives 
of this study were to characterize the local duration of exposure of TA and to assess the safety 
and general tolerability of a single 3 mL IA injection of FX006 (1 0 or 32 mg) relative to 40 mg 
of TAcs .   
Study FX006 -2014 -006 was a Phase 2b, multi -center, randomized, parallel group, dose -ranging 
study.  The primary objectives of this study were to assess the magnitude and duration of pain 
relief of a single 5 mL IA i njection of FX006 (20 mg or 32 mg) relative to placebo (normal 
saline) and assess the safety and general tolerability of FX006.   
FX006 -[ADDRESS_873451] of a single 5 mL IA injection of FX006 ( 32 mg) relative to 40 mg of TAcs  
(active control) in patients with moderately symptomatic post -traumatic osteoarthritis (PTOA) of 
the knee.  Due to the challenges of enrolling military personnel with PTOA, this study was 
discontinued early.  
Study FX006 -2014 -008 was a Phase 3, multi -center,  double -blind, randomized, placebo - and 
active comparator -controlled study. The primary objective of this study was to assess the 
magnitude and duration of pain relief of a single 5 mL IA injection of FX006 ( 32 mg), relative to 
normal saline (placebo contr ol) and 40 mg of TAcs  (active comparator).   
Study FX006 -2015 -009 was a Phase 2, open -label, single administration study.  The objectives 
of this study were  to characterize the local extent and duration of exposure of TA from FX006 
and TAcs , characterize t he systemic PK  of FX006 and TAcs , and assess the safety and general 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 21 of 57 
 tolerability of a single 5 mL IA injection of 32 mg FX006 relative to  40 mg of TAcs  in patients 
with OA of the knee . 
Study FX006 -2015 -010 was a Phase 2, multi -center, double blind, randomi zed, parallel group 
study.  The primary objective of this study  was the assessment of the effects of a single 5 mL IA 
injection of FX006 ( 32 mg) on blood glucose levels in patients with type [ADDRESS_873452] -dose, and slow elimination from 
the systemic circulation observed in the weeks thereafter .  
Relative to TAcs, FX006 32 mg produced substantially lower peak plasma and systemic 
exposure to TA. FX006 performed as expected, prolonging the residence of TA in the joint while 
minimizing systemic exposure to TA.  
5.2.6.  Clinical Pharmacodynamics  
In Study FX006 -2011 -002, s uppression of cortisol in the days following injection produced by 
[CONTACT_941] 10 and 40 mg dose of FX006 was less than that produced by [CONTACT_538732] ; the 60 mg 
dose of FX006 produced effects similar to TAcs 40 mg. Cortisol suppression  subsequent to Day 
1-2 associated with all doses of FX006 would not be expected to be of clinical consequence in 
adult patients without otherwi se comprised HPA axis function.  
In Study FX006 -2015 -010, treatment with FX006 32 mg resulted in a statistically s ignificant 
(p=0.0452) reduction in blood glucose elevation relative to TAcs  over a 72 -hour period 
following IA injection . The time in glycemic target range (70 -180 mg/dL) (American Diabetes 
Association, 2016 ) was greater for FX006 as compared to TAcs over the [ADDRESS_873453] injection glucose monitoring period, blood glucose levels 
associated with FX006 remained at levels similar to or lower than those produced by [CONTACT_538733] . This 
observation is consistent with PK studies demonstrating low systemic exposure to TA associated 
with FX006.  
5.2.7.  Clinical Efficacy  
[IP_ADDRESS].  Study FX006 -2011 -001 
In Study FX006 -2011-001, a dose -ranging, active comparator trial of a single IA injection of 
FX006 in patients with OA of the knee:  
 The 40 mg dose of FX006 produced a statistically significant (p<0.05, 1 -sided) and 
potentially clinically meaningful improvement in pain reli ef relative to TAcs  between 
Weeks 5 and 10 and also demonstrated significant improvement over TAcs  (p<0.05, 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 22 of 57 
 1-sided) at Week 8 in secondary outcomes that assessed pain, stiffness, function, 
PGIC , and CGIC.  
 The 60 mg dose did not provide additional benefit relative to the 40 mg dose of 
FX006.  
 The median time to onset of pain relief was similar across all treatments, occurring 1 
to 2 days following injection. (Bodick et al, 2015 ) 
[IP_ADDRESS].  Study FX006 -2014 -006 
In Study FX006 -2014 -006, a P hase 2b dose -ranging, placebo -controlled trial of a single IA 
injection of FX006 in patients with OA of the knee:  
 The [ADDRESS_873454], which persisted through Week 9 with FX006 20 mg and through 
Week 13 with FX006 32 mg. In secondary outcomes that assessed pain, stiffness, 
function, and Patient and Clinical Global Impressions of Change, 32 mg FX006 
demo nstrated significantly better or trending better outcomes versus placebo at 
Weeks 4, 8 , and 12.  
 The [ADDRESS_873455], and prolonged duration of action relative to placebo.  
[IP_ADDRESS].  Stud y FX006 -2014 -008 
In Study FX006 -2014 -008, a Phase 3 double -blind, randomized, single -dose study to assess the 
safety and efficacy of FX006 for the treatment of pain in patients with OA of the knee:  
 [ADDRESS_873456] relative to 
placebo.  
 When compared to 40 mg TAcs , 32 mg FX006 was numerically superior at Weeks 2 
throug h 19 on the weekly mean of average daily pain ( ADP ) scores, although it did 
not achieve statistical significance, likely as a result of an unexpected  loss of assay 
sensitivity in that measure. However, in pre -specified exploratory OA specific 
measures, com pared to 40 mg TAcs , 32 mg FX006 achieved statistical significance 
through 12 weeks on WOMAC A (pain), WOMAC B (stiffness), and WOMAC C 
(function) and the validated KOOS QOL subscale.  
 A single IA injection of 32 mg FX006 was well tolerated, with systemic and local 
safety profiles generally similar to placebo and 40 mg TAcs  
5.2.8.  Clinical Safety  
The evaluation of 687 patients treated with a single IA injection of FX006 at any dose  in the 
FX006 clinical studies  suggests that it was well tolerated with systemic and local safety profiles 
similar to those of TAcs  and placebo.   
The safety data from the completed FX006 clinical studies are largely consistent.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 23 of 57 
  The number of treatment -emergent adverse events (TEAEs) reported was similar 
across groups (FX006 46.0%; placebo 49.2%; TAcs 51.0 %). 
 The majority of TEAEs in FX006 -treated patients were mild or moderate (Grade 1 or 
2).  Severe or life threatening events occurred in the FX006 -treated patients at a rate 
of 3.0% as compared to 5.0% and 2.6% in the placebo and TAcs  groups, respectively,  
 In the FX006 -treated patients  (n=687) , the most common TEAEs were:  
 Arthralgia (in any joint) 9. 8% (n= 67) 
 Headache 5. 4% (n= 37) 
 Upper Respi[INVESTIGATOR_59398] 3. 1% (n= 21) 
 Joint swelling 2.8% (n=19)  
 Contusion and back pain 2.3% (n=16)  
 Nasopharyngitis 2.2% (n=15)  
 The rate of serious adverse events (SAEs) was low and consistent across groups 
(FX006 1. 9%; placebo 1.1% ; TAcs  2.3%); none were considered related to the study 
drug.  
 Acros s all studies there were no deaths.  
In Study FX006 -[ADDRESS_873457] injection included joint space narrowing (JSN), subchondral bone changes, 
osteonecrosis, and insufficiency fracture.  
 The overall rate of JSN worsening of at least 1 -grade between baseline and Week 24 
was low and similar among treatment groups (5.0% [7/140], 4.1% [6/148], and 3.5% 
[5/145] of patients with both baseline and Week 24 X -rays in the FX006 32 mg, 
placebo, and TA cs groups respectively); for all but 1 of these 18 patients, JSN 
worsened by 1 grade only. The remaining patient (in the placebo group) had a 2 -grade 
worsening in JSN (from 0 at baseline to Grade 2 at Week 24).  
 No FX006 -treated patient had X -ray evidence o f treatment -emergent insufficiency 
fracture, subchondral bone changes, or osteonecrosis at Week 24.  
 Eighteen patients discontinued the study prior to Week 24 and completed a final X -
ray as part of early termination visit. Of these, 2 patients, 1 in the FX0 06 32 mg group 
and 1 in the placebo group, had a 1 -grade increase in JSN. There were no reports of 
insufficiency fracture, subchondral bone changes, or osteonecrosis.  
Please refer to the current Investigator’s Brochure  for further safety details.  
5.2.9.  Conclusio n 
These data provide a strong rationale for further clinical study of FX006 and these data also 
provide the ethical basis for future clinical studies . 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 24 of 57 
 6. THESE DATA PROVIDE B ASES FOR CONTINUED C LINICAL 
STUDY OF FX006. STUDY  OBJECTIVES  
6.1. Primary Objective  
The pri mary objective of this study is to assess the overall safety and general tolerability of 
repeat administration  of FX006 (two doses of  32 mg FX006 ) in patients with symptomatic OA of 
the knee.  
6.2. Exploratory Objective  
Exploratory objective s of this study  include the following:  
 examine efficacy signals for sustained pain reduction following two doses of 32 mg 
FX006.  
 collect synovial fluid samples to enable  potential  future examination  of synovial fluid 
biomarkers  that may contribute to the pathogenesis of OA and/or be associated with  
responsiveness to FX006 treatment .   
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 25 of 57 
 7. INVESTIGATIONAL PLAN  
7.1. Overall Study Design and Plan  
This study is an open -label, repeat administration design of 32 mg FX006. The study will be 
conducted in male and female patients ≥ [ADDRESS_873458] initial injection at: Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, [ADDRESS_873459] initial injection at: Weeks 4, 8, [ADDRESS_873460] initial injection at : Weeks 4, 8, 12, 16, [ADDRESS_873461] of the study at his/her site, 
ensuring that sufficient and appropriately experienced staff are available to conduct the trial and 
ensuring that activities are appropriately delegated and documented.  Any delegation of 
responsibilities will be documented in a study -specific Clinical Site  Responsibilities  and 
Signature  [CONTACT_26500].  The term ‘Principal Investigator’ is used throughout this protocol to refer to the 
actual Principal Investigator [INVESTIGATOR_1238]/or his/her delegated team member(s) for the specific 
responsibility being described.  
Pharmacist/coordi nator  
 must be a registered pharmacist or an individual with the qualifications and training 
required to handle and prepare study medications  
 is responsible for handling and preparing all study medications and maintaining 
investigational product accountabi lity records  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 26 of 57 
 Injector/Aspi[INVESTIGATOR_13521]   
 must be a medical doctor, a physician’s assistant , or nurse practitioner e xperienced in 
administering IA injections and performing synovial fluid aspi[INVESTIGATOR_651324]  
 is responsible for performing IA injections of study medication and synovial fluid 
aspi[INVESTIGATOR_651325]   
 must be a medical doctor, a physician’s assistant , or nurse practitioner  
 must have relevant OA experience  
 responsible  for performing the physical examination and index knee assessments and 
assessing causality of an adverse event (AE) or SAE.  
The same individual may serve in multiple roles (e.g., a physician sub -investigator may serve as 
both the Injector/Aspi[INVESTIGATOR_651326]/or  Assessor).  
7.3. Discussion of Study Design  
7.3.1.  Rationale for Study Population  
Patients with  pain associated with  OA of the knee as defined by [CONTACT_651348] (for example, hypertens ion) that 
are well controlled are included.  In general this population tolerates IA injections of 
commercially available corticosteroids ( Habib 2009 ).  In prior clinical studies of FX006 in this 
population, single injections of up to 60 mg of FX006 were well tolerated.  
7.3.2.  Rationale for Dose Selection  
The rationale supporting dosing at this level couples nonclinical data summarized in the 
Investigator Brochure (Section 4), and clinical experience with FX006.  In study F X006 -2011 -
001, the prior dose -ranging study that included 10, 40, and 60 mg doses of FX006 and TAcs  
(e.g., Kenalog®-40 Injection), a dose response was evident between 10 and 40 60 mg doses over 
the entire 12 weeks of therapy. At no point in the course of t herapy did the 60  mg dose provide 
additional improvement relative to the 40 mg dose. Thus, it was assumed that the minimum dose 
to achieve maximal efficacy was >10 and ≤40 mg.  As well, 40 mg FX006 has been shown to be 
well tolerated in previous single dos e clinical trials . 
7.3.3.  Rationale for Study Design  
Evidence from non -clinical repeat dose studies, the overall safety profile of 32 mg FX006 being 
well tolerated and the common practice of repeating corticosteroid injections support the 
evaluation of repeat administration of 32 mg FX006.   
7.3.4.  Rationale for Study Parameters  
The clinical safety parameters to be assessed (adverse events, physical examinations, index knee 
examinations, index knee X -rays, vital signs, and clinical laboratory evaluations) are standard  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 27 of 57 
 safety and tolerability assessments and support the clinical monitoring necessary based on the 
toxicology profile for FX006.  
The efficacy parameters to be assessed are recommended outcome measures for the assessment 
of chronic pain ( Dworkin et al, 2005 ). 
7.4. Selection of Study Population  
7.4.1.  Number of Patient s 
Approximately [ADDRESS_873462] 100 patients  receive two doses 
of FX006 and complete the study through Week 52.  
7.4.2.  Screening Criteri a 
[IP_ADDRESS].  Screening Inclusion Criteria  
To be included in the trial, patients must fulfill the following criteria:  
1. Written consent to participate in the study  
2. Willingness and ability to comply with the study procedures and visit schedules and 
ability to follow ver bal and written instructions  
3. Male or female 40 years of age  
4. Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening 
(patient  self-report is acceptable)   
5. Currently meets ACR Criteria (clinical and radiological) for OA ( Altman et al, 1986 ) as 
follows:  
 Knee pain  
 at least 1 of the following:  
o Age > 50 years  
o Stiffness < 30 minutes  
o Crepi[INVESTIGATOR_72831]  
 Osteophytes  
6. Kellgren -Lawrence (KL) Grade  2, 3 or 4  in the index knee based on X -ray performed 
during Screening ( locally read)  
7. WOMAC A total sum score of ≥ 6 at Screening and Day 1/Baseline  
8. Index knee pain for >[ADDRESS_873463] month (as reported by [CONTACT_11581] t) 
9. If bilateral OA exists, pain in the con tralateral knee must be less than pain in the index 
knee as reported by [CONTACT_102]  
10. Body mass index (BMI) ≤ 40 kg/m2 s 
11. Ambulatory and in good general health  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 28 of 57 
 12. Willingness to abstain from use of the following protocol -restricted medications during 
the study:  
 Intravenous (IV), intramuscular (IM) , and oral corticosteroids  (Note: inhaled, 
intranasal , and topi[INVESTIGATOR_569506]) 
 IA corticosteroids in any joint  
 IA viscosupplementation (hyaluronic acid) or any IA intervention (IA injection, IA 
aspi[INVESTIGATOR_39870] n, etc.) in the index knee  
 Opi[INVESTIGATOR_2573] s  
 Any investigational drug, device , or biologic  
 Immunomodulators, immunosuppressives, or chemotherapeutic agents  
 Live or live attenuated vaccines  
[IP_ADDRESS].  Screening Exclusion Criteria  
Patients fulfilling at least one of the following criteria may not be included in the study:  
Disease -related criteria  
1. Reactive arthritis , rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, or 
arthritis associated with inflammatory bowel disease  
2. History of infection in the index knee joint  
3. Clinical signs and symptoms of active knee infection or crystal disease of the index knee 
within 1 month of Screening  
4. Presence of surgical hardware or other foreign body in the index knee  
5. Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months of 
Screening  
Previous or concomitant treatment -related criteria  
6. IA corticosteroid (investigational or marketed) in index knee within 3 months of 
Screening   
7. IA hyaluronic acid (investigational or marketed) in the index kn ee within 6 months of 
Screening  
8. IV or IM corticosteroids (investigational or marketed) within 3 months of Screening  
9. Oral corticosteroids (investigational or marketed) within 1 month of Screening  
10. Any other IA drug/biologic use within 6 months of Screening o r 5 half -lives (whichever 
is longer)  (e.g., platelet rich plasma (PRP) injection, stem cells, prolotherapy , and 
amniotic fluid injection ) 
11. Prior administration of FX006  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 29 of 57 
 12. Prior arthroscopic or open surgery of the index knee within 12 months of Screening  
13. Planned/anticipated surgery of the index knee during the study period  
Patient -related criteria  
14. Known hypersensitivity to any form of triamcinolone  
15. History of sarcoidosis or amyloidosis  
16. Active or history of malignancy within the last 5 years, with the exceptio n of resected 
basal cell carcinoma, squamous cell carcinoma of the skin, or effectively managed 
cervical carcinoma  
17. Known active or quiescent systemic fungal, bacterial , mycobacterial  (including 
tuberculosis), viral or parasitic infections, or , shingles, he rpes zoster , and ocular herpes 
simplex  
18. Any infection requiring IV antibiotics within 4 weeks of Screening or oral antibiotics 
within 2 weeks of Screening  
19. History of osteomyelitis  
20. Known or clinically suspected infection with human immunodeficiency virus (H IV), 
hepatitis B or C viruses  
21. Any clinically significant electrocardiogram (ECG) abnormality as judged by [CONTACT_3786]  
22. Patients requiring or likely to require chronic treatment with corticosteroids during the 
study period based on patient medical histo ry 
23. History of or active Cushing’s syndrome  
24. Active substance abuse (drugs or alcohol), history of chronic substance abuse within the 
past year, or prior chronic substance abuse judged by [CONTACT_651349]  
25. Skin breakdown at  the knee where the injection would take place  
26. Women who are pregnant or nursing  or plan to become pregnant during the study; men 
who plan to conceive during the study  
27. Women of child -bearing potential (not surgically sterile or post -menopausal for at least  1 
year as documented in medical history) not using a highly effective method of 
contraception [abstinence; oral, injected , or implanted hormonal methods of 
contraception; intrauterine device or intrauterine system; condom or occlusive cap 
(diaphragm or ce rvical/vault caps) with spermicidal foam/gel/film/cream/suppository; or 
male sterilization (vasectomy)]  
28. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents within 5 
years of Screening  
29. Has received a live or live attenuated vaccine with in 3 months of Screening  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 30 of 57 
 30. Use of any other investigational drug or device within 30 days of Screening or within 5 
half-lives (whichever is longer) or an investigational biologic within 60 days of Screening 
or within 5 half -lives (whichever is longer)  
31. Any other clinically significant acute or chronic medical conditions (e.g., bleeding 
disorder) that, in the judgment of the Investigator, would preclude the use of an IA 
corticosteroid or that could compromise patient safety, limit the patient’s ability to 
complete the study, and/or compromise the objectives of the study  
7.4.3.  Repeat Administration Criteria  
Patients who receive an initial injection of FX006 must meet the following criteria in order to 
receive  a repeat administration . 
[IP_ADDRESS].  Repeat Administration Inclusion C riteria  
To be eligible to receive a repeat administration, patients must fulfill the following criteria:  
1. Benefit from the initial dose of FX006  in the opi[INVESTIGATOR_651322]  
2. No major safety concerns during the initial dose period  as assessed by [CONTACT_737]  
3. Clinically indicated to receive a second dose of FX006 in the opi[INVESTIGATOR_651327]  
4. WOMAC A total sum score of ≥ [ADDRESS_873464] Week 12 and the 
willingness and ability to continue to comply through Week 52   
6. Willingness to abstain from use of protocol -restricted medications during the study   
[IP_ADDRESS].  Repeat Administration Exclusion Criteria  
Patients fulfilling at least one of the following criteria may not receive repeat administration : 
1. Clinical signs and symptoms of active knee infection or crystal disease of the index knee  
2. Received a  non-protocol specified  IA intervention (IA injection, IA  aspi[INVESTIGATOR_1516], etc.) in 
index knee during study participation  
3. Use of immunomodulators, immunosuppressives, or chemotherapeutic agents during 
study participation  
4. Received a live or attenuated vaccine  during study participation  
5. Use of any other investigational  drug, device , or biologic during study participation  
6. Allergic reaction to initial dose of FX006  
7. Any infection requiring IV antibiotics within [ADDRESS_873465]  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 31 of 57 
 9. Women who are pregnant or nursing or plan to become pregnant during the study; men 
who plan to conceive during the study  
10. Women of child -bearing potential (not surgically sterile or post -menopausal for at least 1 
year as documented in medi cal history) not using a highly effective method of 
contraception [abstinence; oral, injected , or implanted hormonal methods of 
contraception; intrauterine device or intrauterine system; condom or occlusive cap 
(diaphragm or cervical/vault caps) with sperm icidal foam/gel/film/cream/suppository; or 
male sterilization (vasectomy)]  
11. Any other clinically significant acute or chronic medical conditions (e.g., bleeding 
disorder) that, in the judgment of the Investigator, would preclude the use of an IA 
corticoster oid or that could compromise patient safety, limit the patient’s ability to 
complete the study, and/or compromise the objectives of the study  
7.4.4.  Removal of Patients  from Therapy or Assessments  
Each patient will be informed of his/her right to discontinue from  the study at any time for any 
reason and without prejudice to alternative treatment.  The Principal Investigator [INVESTIGATOR_651328] a patient from the study at any time if, for example, he/she considers the patient’s 
health to be compromised by [CONTACT_651350] g in the study, or the study is prematurely terminated.  In 
these cases the Principal Investigator [INVESTIGATOR_1318]:  
1. attempt to complete the study assessments defined for the Early Termination Visit*  
2. determine whether the patient is willing to be contact[CONTACT_107810] o ngoing or new AEs 
through Week 12 for patients who only receive a single injection, or through Week 52 for 
patients who receive a second injection  (if reason for discontinuation is not “withdrew 
consent”)  and contact [CONTACT_651351] (via phone or in -person). Concomitant 
medications associated with any AE will also be captured.  
3. document patient consent in the source document for continued follow -up 
*Note: Early Termination visits should follow the Week [ADDRESS_873466] Arm :  
FX006 – extended -release formulation of TA formulated in in 75:25 PLGA microspheres.  
Nominal 32mg TA, administered as a single 5 mL IA injection  
Reference Compound:  
Not applicable  
7.5.2.  Identity of Investigational Product(s)  
FX006 is supplied as a sterile, white to off-white  powder in a single unit dose 5 mL vial with a 
butyl rubber stopper, aluminum seal , and plastic cap.  FX006 is reconstituted in diluent 
containing an isotonic, sterile aqueous solution of sodium chloride (N aCl; 0.9% w/w), 
carboxymethylcellulose sodium (CMC; 0.5% w/w) , and polysorbate -80 (0.1% w/w) to form a 
suspension prior to IA injection.  Diluent will be supplied as a sterile liquid in a 5 mL vial with a 
butyl rubber stopper, aluminum seal , and plastic ca p.  FX006 will be reconstituted in 5.0 mL of 
diluent to form a suspension immediately prior to IA injection.  FX006 will be administered as a 
single 5 mL IA injection.  
7.5.3.  Receipt, Dispensing , and Storage  
Study medication will be shipped to the site from the d rug supply distribution center  as a 
packaged kit .  Receipt and dispensation of study medication will be properly documented within 
the Drug Tracking Module . Any temperature excursions should be documented in the Drug 
Tracking Module for Sponsor assessment and authorization for continued use . 
The packaged kits will be stored in a secure area  and will be stored refrigerated a t 2 to 8°C.  
7.5.4.  Packaging and Labeling of Study Medication  
The packaged kit will contain one (1) vial of FX006, one (1) vial of Diluent, and  a vial adapter.   
The FX006 and diluent vial s will be labelled with their respective unique lot numbers within the 
packaged  kit, which will be affixed with its own label and kit number.     
7.5.5.  Return of Study Medication  
All study medications (packaged kits /used and unused vials) will be returned to the Sponsor .  
Return of study medications will be properly documented.  
7.5.6.  Method of Assigning Patient s to Treatment Groups  
This is a single -arm, open -label study.  All eligible patients will receive one or two doses of 
FX006 .  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 33 of 57 
 7.5.7.  Blinding  
This is an open -label study.  
7.5.8.  Intra -articular Injection Procedure  
IA injections will be performed by [CONTACT_538726].  The injector may choose the position of 
the knee (e.g., extended or flexed ), the approach for th e injection (e.g., medial or lateral) and the 
numbing agent to be used (e.g., ethyl chloride, subcutaneous lidocaine; IA anesthetics are not 
allowed) based on standard of care. Sterile technique should be used.   
Prior to injection, the index knee should b e thoroughly cleansed using a bactericidal solution.  
The index knee will be aspi[INVESTIGATOR_569507].  
Following attempted aspi[INVESTIGATOR_1516], [ADDRESS_873467] to physical activity throughout the durat ion of the study.  
In the event that the patient has an immediate reaction (e.g., tenderness, increased pain, swelling, 
effusion, decreased mobility of the index knee), the patient should be treated according to local 
clinical guidelines and physician exper ience (see also Protocol Section Section  8.1.5 ). 
7.5.9.  Treatment Compliance  
Study medication will be administered by [CONTACT_538741].  Details regarding study 
medication administration will be documented in the electronic Case Report Form (eCRF).  The 
receipt, dispensation , and return of any study medication will be properly documented.  
If for any reason the administration of study medication is stopped before the entire volume is 
injected, the injector should document the reason for stoppi[INVESTIGATOR_632065].  
7.6. Prior and Concomitant Therapy  
During the study, all existing (prior to study entry), new , or changes in concomitant medications 
and the assoc iated reasons for use or change will be documented and reported.  
7.6.1.  Allowable Medications /Therapi[INVESTIGATOR_651329]:  
 Any treatment for a pre -existing condition or for an AE, including the study 
indication (e.g., analgesic medications), that is not listed  as restricted  below  
 Physical therapy for index knee  
 Bracing of index knee  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 34 of 57 
 7.6.2.  Restricted Medications  
The exclusion criteria indicate that a patient may not be enrolled if he/she has used any of the 
following within the specified windows detailed in the Exclusion criteria (Section  [IP_ADDRESS] ).  In 
addition these medications should not be taken or used throug hout the study:   
 IV, IM , or oral corticosteroids  (Note: inhaled, intranasal , and topi[INVESTIGATOR_651330])  
 IA corticosteroids in any joint  
 IA viscosupplementation (hyaluronic acid) or any IA intervention (IA injection, IA 
aspi[INVESTIGATOR_1516], etc.) in t he index knee  
 Opi[INVESTIGATOR_2573] s  
 Any investigational drug, device , or biologic  
 Immunomodulators, immunosuppressives, or chemotherapeutic agents  
 Live or live attenuated vaccines  
7.7. Study Variables  
7.7.1.  Safety Variables   
Safety and tolerability will be evaluated on the basis  of AEs spontaneously reported by [CONTACT_538746]: physical 
examinations, index knee assessments, vital signs, and clinical laboratory evaluations.   In 
addition the index knee will b e evaluated by X -ray and assessed by a central imaging vendor for 
joint space narrowing, chondrolysis, subchondral bone changes, bone infarcts, avascular 
necrosis, joint swelling , and insufficiency fracture.  
7.7.2.  Exploratory E fficacy Variables  
 Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index (Likert 
(LK) 3.1, 5 -point scale): pain, stiffness and function domains independently and 
collectively ( Bellamy et al, 1988 ).  
 Knee injury and Osteoarthritis Ou tcome Score (KOOS) Quality of Life (QOL) 
Subscale ( http://www.koos.nu/ ). 
 Daily activity measured as steps per day.  
 Global Physical Activity Questionnaire (GPAQ) domains for occupational physical 
activity, transport -related physical activity, and physical activity during discretionary 
or leisure time ( http://www.who.int/chp/steps/GPAQ/en/  ) 
7.7.3.  Pharmacody namic Variables  
Synovial fluid samples will be preserved for  potential  future analyses of biomarkers that may 
contribute to the pathogenesis of OA and/or be associated with responsiveness to FX006 
treatment .   
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 35 of 57 
 7.8. Schedule of Study Assessments  
A summary of the schedule of a ssessments is provided  in Table 1.   
Refer to Section 7.9 for details of each assessment.  
  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 36 of 57 
 Table 1: Schedule of Study Assessments  
Procedures  Screen1 
 Baseline  
Day 1  Week  
42 Week  
82 Week  
12, 16, 20, 242 Week  
28, 32, 36, 40, 44,  482 Week  
522/End of Study  
Informed consent  X3       
Inclusion/Exclusion Review  X X4      
Medical History/Update  X X4      
OA Medical History  X       
Prior Treatment & Medications  X5 X4      
Physical Examination  X    X6  X 
Index Knee X -ray7 X      X8 
Index Knee Assessment9 X X4   X6  X 
12-Lead ECG  X       
Vital Signs  X X4   X6  X 
Height  X       
Weight and BMI  X      X 
Hematology & Chemistry10 X    X6  X 
HIV, Hepatitis B/C10 X       
Serum Pregnancy Test10,[ADDRESS_873468] treatment administration   X      
Evaluation for  repeat administration      X   
2nd (repeat) treatment administration      X16   
AEs & ConMeds17  --------------------- ------------------------------ X------------------------------ ---------------------  
                                                 
1 Screening period is a minimum of 7 days, up to 21 days.  
2 Visit should be conducted within +/ - [ADDRESS_873469] any prior medications received within 30 days prior to the Screening visit . 
6 To be completed prior to dosing only if patient is to receive the 2nd dose of FX006. For patients not eligible to receive 2nd dose, complete at the 
final study visit.  
7 Standing, fixed flexion PA view, weight bearing X -ray of the index knee will be take n using a standardized knee positioning device.  The 
Screening X -ray will be read locally for K -L grade.  The Screening and Week 52 X -rays will be sent to central imaging vendor for safety 
assessment.  
8 End of Study x -ray will only be performed if patient has received a repeat administration of FX006 . 
9 Index knee will be assessed for tenderness, heat/redness, swelling, effusion, and Baker’s cyst. New clinically significant fi ndings or findings that 
worsen for the patient’s baseline condition should be reco rded as AEs.  
[ADDRESS_873470] 7 days prior to Baseline/Day 1 through Week 12. The site will confirm patient compliance with wearing the device to capture steps per 
day data at each patient visit from Day 1 through Week 12.  
15 To be completed prior to dosing only if patient is to receive the 2nd dose of FX006.  
16 Repeat administration may occur at either Week 12, 16, 20 , or 24. 
17 AEs and Concomitant  Medications will be captured from Day 1 (post injection) to Week 12 or 24 for patients who only receive a single 
injection or to Week 52 for patients who receive a second injection or to Early Discontinuation Visit for patients who discon tinue the study 
early.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 37 of 57 
 7.9. Study Procedures  
[IP_ADDRESS].  Informed Consent  
Prior to initiation of any study related procedures, patients will review and sign the study’s 
informed consent form to participate in the study after having been informed about the nature 
and purpose of the study, participation and termination conditions, and risks and benefits.  
7.9.2.  Review of Eligibility, Medical History, Prior Treatment , and Medications  
Eligibility criteria (inclusion and exclusion criteria), medical history (including OA history), 
prior treatment and medications are reviewed during screening and again at Baseline/Day 1.  
OA medical history includes ACR diagnosis de tails, OA diagnosis date (if available), K -L grade 
(See Appendix 1), number of days with index knee pain in the last month, and previous IA 
steroid or hyaluronic injections.  
7.9.3.  Physical Examination  
The physical exam will assess the following body systems:  
1. General Appearance  
2. Skin 
3. Lymphatics  
4. HEENT (head, ears, eyes, nose, throat)  
5. Cardiovascular  
6. Respi[INVESTIGATOR_696]  
7. Abdominal  
8. Musculoskeletal  
9. Neurological  
Any clinically significant findings must be documented in the source and added to the medical 
history if found at Screening or recorded as an AE if new or worsened from baseline at one of 
the post -baseline visits.  
7.9.4.  Index Knee X -ray 
A diagnostic quality X -ray of the index knee is required (standing, fixed flexion PA view; 
weight -bearing; use of standardized knee positio ning device is required) at Screening and Week 
52 (for patients that receive a second injection) . The Screening X-ray will be read locally for K -L 
grading by a radiologist or clinician with rheumatology or orthopedic specialty .  In addition , the 
Screening and Week 52 X -rays will be sent to the central imaging vendor for  safety assessments.  
An image acquisition protocol will be distributed to sites with simple instructions for radio -
anatomic positioning for reliable grading.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 38 of 57 
 7.9.5.  Index Knee Assessment  
The index k nee assessment will be performed by [CONTACT_651352] 1.  The index knee will be assessed for tenderness, heat/re dness, swelling, effusion, and 
Baker’s cyst.  If there is a clinically significant finding  outside of the patient’s typi[INVESTIGATOR_651331], add to the Medical History.  At time points post -baseline, 
if there are new clinic ally significant findings  outside of the patient’s typi[INVESTIGATOR_651332]’s baseline condition, record as AEs.  
7.9.6.  12-lead ECG  
At Screening, a 12 -lead ECG will be obtained in the supi[INVESTIGATOR_2547].   Measures of heart rate , PR 
interval, RR interval, QT  interval, QTc (corrected for Bazett’s or Fridericia’s) interval and QRS 
duration will be obtained.  If QTc > 450 msec for male patients or > [ADDRESS_873471] be collected approximately 1 minute apart.  ECGs will be locally read and a 
copy of each recording will be kept with the patient’s source documentation.  
7.9.7.  Vital Signs  
Vital signs are to be taken at the days indicat ed in the  Table 1. The following measurements will 
be taken: sitting blood pressure, heart rate, respi[INVESTIGATOR_1487], and temperature.  
7.9.8.  Height, Weight , and BMI determination  
Height and weight are to be taken at the days indicated in the  Table 1.   Height will be measured 
in centimeters or inches. Weig ht will be measured in kilograms or pounds. BMI will be 
calculated using the formulas in  Table 2 (reference: www.cdc. gov): 
Table 2: BMI Calculations  
Measurement Units  Formula and Calculation  
Kilograms and meters (or 
centimeters)  Formula: weight (kg) / [height (m)]2 
With the metric system, the formula for BMI is weight in kilograms divided by 
[CONTACT_55739]. Since height is commonly measured in centimeters, divide 
height in centimeters by 100 to obtain height in meters.  
Example: Weight = 68 kg, Height = 165 cm (1.65 m)  
Calculation: 68 ÷ (1.65)2 = 24.98  
Pounds and inches  Formula: weight (lb) / [height (in)]2 x 703  
Calculate BMI by [CONTACT_538748] (lbs) by [CONTACT_538749] (in) squared 
and multiplying by a conversion factor of 703.  
Example: Weight = 150 lbs, Height = 5'5" (65")  
Calculation: [150 ÷ (65)2] x 703 = 24.96  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 39 of 57 
 7.9.9.  Central Clinical Laboratory Evaluations  
Blood samples will be taken at the days indicated in the  Table 1.  The specific laboratory panels 
to be run can be found in Table 3.  Follow the Central Laboratory Manual for detailed sample 
collection, handling, storage, and shippi[INVESTIGATOR_3931].  
Table 3: Clinical Laboratory Panel  
HEMATOLOGY  CLINICAL CHEMISTRY  
Hemoglobin  Sodium  
Hematocrit  Potassium  
Erythrocyte count (RBC)  Bicarbonate  
Mean cell volume  Chloride  
Leukocytes (WBC)  Calcium   
Absolute counts of:  Total bilirubin  
 Neutrophils  Alkaline phosphatase  
 Lymphocytes  Alanine aminotransferase  
 Monocytes  Aspartate aminotransferase  
 Eosinophils  Blood urea nitrogen  
 Basophils  Creatinine  
 Platelets  Uric acid  
INFECTIOUS DISEASES  Total protein  
Hepatitis B Surface Antigen  Albumin  
Hepatitis C Antibody  Glucose  
HIV   
SERUM PREGNANCY TEST (women of 
child -bearing age only)   
URINE PREGNANCY TEST (women of 
child -bearing age only) test provided by 
[CONTACT_651353]   
 
7.9.10.  Patient Questionnaires  
The following questionnaires will be completed  by [CONTACT_651354] 1.  
 WOMAC LK 3.1  
 KOOS - Quality of Life Subscale  (Q1-Q4)     
 GPAQ  
7.9.11.  Daily Activity   
Steps per day will be captured  using a measured function device .  Patients will be provided with 
a device at the Screening visit to be worn for at least 7 days  prior to Baseline/ Day 1  through 
Week 12.  The site will confirm  patient compliance with wearing the device to capture steps per 
day data at each patient visit from Day 1  through Week 12.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 40 of 57 
 7.9.12.  Synovial Fluid Aspi[INVESTIGATOR_651333] a spi[INVESTIGATOR_651334]/Day 1 prior to study medication administration and the week 
at which the second dose is administered prior to study medication administration (if the patient 
is eligi ble to receive a second dose).  Patients that are not eligible to re ceive a second dose will 
not have synovial fluid drawn at their final study visit.  The injector/aspi[INVESTIGATOR_651335].  The volume of the synovial 
fluid obtained will be recorded in t he eCRF. If no synovial fluid is obtained then 0 mLs should 
be recorded.  Procedures for sample collection, handling, storage and shipment will be described 
in the Study Laboratory Manual.  The synovial fluid samples  will be preserved for  potential  
future analyses of biomarkers that may contribute to the pathogenesis of OA and/or be associated 
with responsiveness to FX006 treatment .       
7.9.13.  Treatment Administration  
At Baseline/Day 1 and the week at which the second dose is to be administered (if the p atient is 
eligible to receive a second dose), the following will occur:  
 Study medication will be prepared by [CONTACT_32335]/coordinator (Refer to the 
Pharmacy Binder for instructions on how to prepare FX006).   
 Synovial fluid will be aspi[INVESTIGATOR_651336] (refer to Section 7.9.12  for more details of the synovial fluid 
aspi[INVESTIGATOR_1516]).   
 The injecto r/aspi[INVESTIGATOR_651337] (refer to 
Section 7.5.8  for instructions).   
7.9.14.  Review of Adverse Events and Concomi tant Medications  
After receiving study medication, the patient will be monitored for any AEs.  Review of any 
Concomitant Medications will also be performed and documented in source documentation.  
Refer to Section 8.[ADDRESS_873472] study visit.  Results of clinical safety assessments are to be 
recorded in the patient’s medical records and transcribed to the appropriate eCRF, including the 
AE eCRF for clinically significant findings.  
8.1. Adverse Events  
8.1.1.  Definitions  
An AE is any untoward medical occurrence in a patient or clinical investigation patient 
administered a pharmaceutical product and that does not necessarily have a causal relationship 
with this treatment.   
An AE can therefore be :   
 Any unfavorable and unintende d sign (including an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of a medicinal 
(investigational) product, whether or not related to the medicinal (investigational) 
product.  
 Any clinically significant abnormality f ound on an ECG, laboratory test or physical 
examination.  
 Any worsening (i.e., any clinical significant adverse change in frequency and/or 
intensity) of a preexisting condition, which is temporally associated with the use of 
the medicinal (investigational) product, is also an AE.  
An SAE  is any untoward medical occurrence that at any dose:  
 Results in death,  
o This serious criterion applies if the patient’s death is a direct outcome of a 
reported AE.  
 Is life -threatening,  
o This serious criterion refers to an event in which the patient was at substantial risk 
of death at the time of the event; it does not refer to an event which hypothetically 
might have caused death if it were more severe.   
 Requires inpatient hospi[INVESTIGATOR_5186] n or prolongation of existing hospi[INVESTIGATOR_059],  
o This serious criterion applies if the reported AE requires at least a 24 -hour 
inpatient hospi[INVESTIGATOR_26109], if in the opi[INVESTIGATOR_1237], 
prolongs an existing hospi[INVESTIGATOR_059].  A hospi[INVESTIGATOR_651338] a routinely scheduled treatment is not an SAE by [CONTACT_538752] a 
“procedure” or a “treatment” is not an untoward medical occurrence.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 42 of 57 
  Results in permanent or significant disability/incapacity, or  
o This serious crite rion applies if the “disability” caused by [CONTACT_318378] a substantial disruption of the patient’s ability to carry out normal life 
functions.  
 Is a congenital anomaly/birth defect.  
o This serious criterion applies if a patient exposed to a medic inal (investigational) 
product gives birth to a child with congenital anomaly or birth defect.  
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_79467].  These should 
also usually be considered seri ous. 
Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059]; or 
development of drug dependency or drug abuse.  
8.1.2.  Evaluating and Recording  of Adverse Events  
At each visit all AEs that occur from the time of treatment and throughout a patient’s study 
participation that are observed, elicited by [CONTACT_538753] , or reported by [CONTACT_102], will be 
recorded in the source documentation and ap propriate section of the AE eCRF and evaluated by 
[CONTACT_651355] . 
Minimum information required for each AE includes type of event, duration (start and end 
dates), severity, seriousness, causality to investigational medicinal product, action taken, and 
outcome . 
Severity of AEs will be graded by [CONTACT_079] [INVESTIGATOR_538712] (CTCAE) version 4.0 (refer to the Study Manual or 
http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm ).   
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 43 of 57 
 For AEs not listed in the CTCAE, the following definitions should be used : 
Grade 1  Mild  
Symptomatic or mild symptoms  
Clinical or diagnostic observations only  
Intervention not indicated  
Grade 2  Moderate  
Minimal, local or noninvasive intervention indicated  
Limiting age -appropriate instrumental activities of daily living ( ADL )* 
Grade 3  Severe or medically significant but not immediately life -threatening  
Hospi[INVESTIGATOR_651339]**  
Grade 4  Life-threatening consequences  
Urgent intervention indicated  
Grade 5  Death related to AE  
*Instrumental ADL refer to preparing meals,  shoppi[INVESTIGATOR_3112], using the telephone, managing 
money, etc.  
**Self care ADL refer to bathing, dressing and  undressing, feeding self, using the toilet, taking medications, and not 
bedridden.  
The relationship of the AE to the investigational medicinal product should be specified by  [CONTACT_1268], using the following definitions:  
1.  Not Related:  Concomitant illness, accident or event with no reasonable association 
with treatment.  
2.  Unlikely:  The reaction has little or no temporal sequence from administration of 
the investigational medicinal product , and/or a more likely alternative 
etiology exists.  
3.  Possibly Related:  The reaction follows a reasonably temporal sequence from 
administration of the investigational medicinal product and follows a 
known response pattern  to the suspected drug; the reaction could have 
been produced by [CONTACT_651356]’s clinical state or by [CONTACT_651357] . 
4.  Probably Related:  The reaction follows a reasona ble temporal sequence from 
administration of study medication ; is confirmed by [CONTACT_651358]; and cannot be reasonably 
explained by [CONTACT_11564]’s clinical state.  
5.  Definitely Relate d: The reaction follows a reasonable temporal sequence from 
administration of study medication; that follows a known or expected 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 44 of 57 
 response pattern to the study medication; and that is confirmed by 
[CONTACT_3895][INVESTIGATOR_256630], and reappearance of the reaction on repeated exposure.  
If discernible at the time of completing an AE eCRF, a specific disease or syndrome rather than 
individual associated signs and symptoms should be identified by [CONTACT_651359] d 
on the appropriate AE  eCRF .  However, if an observed or reported sign, symptom, or clinically 
significant laboratory anomaly is not considered by [CONTACT_63033] a component of a 
specific disease or syndrome, then it should be recorded as a separa te AE on the appropriate AE 
eCRF.  
8.1.3.  Reporting of Serious Adverse Events  
When an SAE occurs, the Investigator or designee must log into the electronic data capture 
(EDC) system and complete the SAE Report form within [ADDRESS_873473] be reported to the Medical Monitor within 24 
hours of receipt by [CONTACT_651360] t he electronic SAE form. 
The updated SAE will automatically be reported to the Medical Monitor or designee 
electronically.  
If one is  unable to log into the EDC system, the SAE hotline  may be contact[INVESTIGATOR_530]  (information 
located in the Investigator Site File in th e Study Contact [CONTACT_4111]).  
All SAEs that occur at a given site should, in addition, be reported by [CONTACT_569550] /EC without undue delay, if applicable according to IRB /EC requirements.  
During the conduct of the study, the Sponsor will provide expedited safety reports ( AEs 
classified as serious, unexpected and  at least possibly  related to investigational product) to the 
investigative sites as notification of new safety findings.  If this occurs, the investigative site 
must report th e information to their IRB /EC per local guidelines  (may be submitted by [CONTACT_651361] a central IRB) . 
8.1.4.  Safety Monitoring Roles  
The site personnel  will carefully monitor each patient throughout the study for possible AEs.  All 
AEs will be documented on the eCRF designed specifically for this purpose, and will be 
followed until either completely resolved or until a stable chronic outcome is determined by [CONTACT_1268] .  SAEs  will be reported in accordance with Section  8.1.3. 
The Medical Monitor must promptly review all information relevant to the safety of an 
investigational new product received from any source.  The Medical Monitor will also review 
alert laboratory results in real time and will contact [CONTACT_651362].  
The medical monitor and the Sponsor will review  safety  data approximately on a quarterly basis, 
accessed through the EDC system and associated reporting tools, in order to identify potential 
safety issues/trends that may not be apparent through individual AE reporting.   If systematic 
review identifies a pattern of concern, Sponsor wi ll take steps to address the issues including , but 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 45 of 57 
 not limited to , modifying the protocol and/or notifying investigator, authorities and 
IRB/ECs.   Each review will be documented and filed in the Trial Master File.   
8.1.5.  Clinical Management of Index Knee -related  Events  
In the event that the patient has an immediate reaction following administration of study 
medication or returns to the clinic with an acute exacerbation (e.g., tenderness, increased pain, 
swelling, effusion, decreased mobility of the index knee ), the patient should be treated according 
to local clinical guidelines and physician experience.   
If the index knee is aspi[INVESTIGATOR_569527], 
the volume of synovial fluid aspi[INVESTIGATOR_538715], s ynovial fluid should be (1) 
cultured, (2) evaluated for presence of crystals , and (3) assessed for white cell count at a local 
laboratory, and the results should be documented.   
Any event that is a change from the patient’s baseline status (new or worseni ng case) should be 
reported as an AE and those meeting the definition of serious  must be reported in accordance 
with Section 8.1.[ADDRESS_873474] be followed for information 
regarding the course of the pregnancy and delivery, as well as the conditi on of the newborn.  
Follow -up information concerning the outcome of the pregnancy should be provided to the 
Sponsor in a timely manner.  Additional follow -up is not needed when a newborn baby [CONTACT_538759].             
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 46 of 57 
 9. STATISTICAL C ONSIDERATIONS  
9.1. Statistical an d Analytical Plans  
A comprehensive statistical analysis plan  (SAP)  will be written and approved prior to database 
lock for this study  that describes the final analyses to be completed for safety and exploratory 
efficacy endpoints . If, after the study has b een completed, changes are made to the statistical 
analysis plan referenced below, these deviations to the plan will be listed, along with an 
explanation as to why they occurred, in the Clinical Study Report (CSR).  The key aspects of 
those analyses are summarized below.  
9.1.1.  Interim Analysis  
No formal interim analysis is planned for  the primary safety endpoints in  this open -label study to 
assess the safety and tolerability of FX006 after repeat administration .  However, interim 
analysis  may be conducted  with exploratory endpoints to examine efficacy signals f ollowing 
administration of one or two doses of 32mg FX006 . These interim analyses on exploratory 
endpoints may be completed for  data review , regulatory updates , and/or publication (or 
presentation at congr esses) for this open -label study. Any interim analysis completed will have 
an interim analysis plan written and approved to describe the purpose and analytical objectives of 
the interim analysis.  Final analyses , described in the protocol and statistical a nalysis plan,  will 
be conducted after completion of the study, when all subjects have either discontinued the study 
early (prior to Week 52) or completed the study through Week 52.  
9.1.2.  Final Analyses  
All final analyses will be completed following database lock . Final analyses specified in the 
protocol and SAP will be completed and reported in the CSR . Interim analyses conducted with 
exploratory endpoints to examine efficacy signals  prior to database lock will also be reported in 
the final CSR.  Post-hoc, or addi tional exploratory analyses,  not defined in the SAP  may be 
completed to further understand ing and elucidat ion of the  study results. Any post -hoc, 
exploratory, analyses completed will be clearly identified as such in the final CSR .  
9.2. General Considerations a nd Methods  
Data collected in this study will be presented using summary tables, figures, and patient data 
listings.  Summary tables will present data by [CONTACT_22975], if applicable, by [CONTACT_22976].  Continuous variables will be summarized usi ng descriptive statistics, specifically the 
number of patients (n), the mean, median, standard deviation, minimum and maximum,  and 
coefficient of variations (%CV) .  Categorical variables will be summarized by [CONTACT_45970].  Confidence interv als will be provided  where appropriate for derived endpoints .  
Figures will be used to support the presentation of certain data.  Sensitivity analyses may be 
performed to examine the effect of missing data, as well as the effect of Baseline imbalance  for 
secondary endpoints . 
All confidence intervals (CIs), statistical tests, and resulting p values will be reported as 2 -sided.  
Significance will be assessed at α = 0.05 level and the significance level will not be adjusted for  
multiple comparisons in  the exploratory  efficacy  endpoint analyses.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 47 of 57 
 9.2.1.  Analysis Populations  
Three main analysis populations are planned for this study as follows:  
 Safety Population: All patients who received study medication . The Safety Population 
will be used to assess safety and tol erability for the primary endpoint.  
 FAS Population: All patients who received study drug and provide at least one post -
baseline efficacy endpoint assessment. The FAS population will be used to examine 
exploratory  efficacy endpoints.  
 Biomarker Population: All p atients who received study medication  and provide  at 
least one  synovial fluid sample for biomarker analysis.  
During the course of this study interim analyses may be completed to examine efficacy signals. 
Populations utilized for those interim analyse s will be clearly defined in an interim analysis plan, 
and in the final CSR.  
9.2.2.  Study Data  
Study data identified in this protocol are to be collected, and source verified, on eCRF at sites 
completing the study.  All study data will be formulated into data set s to provide transparency, 
traceability, and integrity of trial analysis results from collection source. Observed study data 
will be mapped to the  Clinical Data Interchange Standards Consortium  (CDISC ) Study Data 
Tabulation Model (SDTM) and serve as the so urce data from the trial. All study analyses will be 
completed using analysis data sets that are derived from the SDTM and follow the CDISC 
Analysis Data Model (ADaM) architecture.  
[IP_ADDRESS].  Clinical Data – CDISC Study Data Tabulation Model (SDTM)  
Domains will be ma pped to CDISC SDTM version  3.2. No derived data required for analysis are 
included in the SDTM domains. All SDTM domains will be fully documented with define 
documents (DEFINE.XML) and a Study Data Reviewer’s Guide (SDRG) after database lock and 
final anal yses are completed.  
[IP_ADDRESS].  Analysis Data – CDISC Analysis Data Model (ADaM)  
All planned and exploratory analyses will be completed using CDISC compliant ADaM data sets 
derived from the SDTM domains for this study. Analysis data sets will contain all derived study  
endpoints required for analysis. All ADaM analysis data sets will be fully documented with 
define documents (DEFINE.XML) and an Analysis Data Reviewer’s Guide (ADRG) after 
database lock and final analyses are completed.  
9.2.3.  Study  Variables for Assessment  
Please refer to Section 7.7.[ADDRESS_873475] 100 patients who receive two 
doses of FX006 are enrolled and followed for 52 weeks, approximately 200 patients will be 
enrolled based on an estimate that approximately 66% of patients enrol led will be eligible to 
receive a second dose of FX006 and approximately 75% of subjects who receive a second dose 
will complete the study through Week 52.  
9.4. General statistical Methods  
9.4.1.  Demographics and Baseline Characteristics  
Demographic and baseline chara cteristics will be listed by [CONTACT_651363] , and will be 
summarized by [CONTACT_3148].  Frequencies and proportions will be presented for the categorical 
variables and descriptive statistics will be presented for continuous variables.  
9.4.2.  Exposure  
Treatmen t exposure will be listed by [CONTACT_651363] , and will be summarized by [CONTACT_2715] s 
administered, as well as total exposure to FX006 . Time between FX006 exposure (1st and 2nd 
doses) will be summarized.   
9.4.3.  Exploratory Efficacy Analyses  
The examination of eff icacy is exploratory  in this study. Data from the WOMAC® questionnaire 
will be presented in by -patient listings with summary presentation of the data and exploratory 
analyses.  
Analysis of the magnitude of pain relief observed with WOMAC A (pain) , stiffnes s (WOMAC 
B), and function (WOMAC C)  will be explored between patients who receive one  or two  doses 
of FX006 will be explored with longitudinal  mixed model for repeated measures (MMRM)  with 
fixed effects of number of doses (1 or 2) received, and a dose by t ime interaction . Model 
covariates will include study site, and potentially other variables.  Subject will be a random 
effect in the model.  The exact configuration for the MMRM will be fully described in the SAP or 
interim analysis plans.    
A within subject analysis will be completed to examine the differences in WOMAC scores 
following the first dose, and then following a second dose of FX006. Change from baseline for 
the first dose and change from last assessment prior to second dose will be  completed with linear 
models. The details of the linear model will be specified in the SAP Evaluation of dose -response 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 49 of 57 
 will be assessed descriptively with an examination of WOMAC A responses at the time (in 
weeks) of second dose administration to assess th e magnitude of scores at each week that a 
second dose may be administered. The time to maximal pain relief response with WOMAC A  
(pain)  following the first and second doses of FX006 will be examined using a Kaplan -Meier 
(KM) procedure.  
Questionnaire data f rom the GPAQ  domains (occupational physical activity, transport -related 
physical activity, and physical activity during discretionary or leisure time) will be described 
descriptively at the two time points collected ( Screening  and Week 12). The change in G PAQ 
domain scores and total score will be examined with an analysis of variance (ANOVA) model 
with summaries comparing patients who receive one dose to those receiving two doses of 
FX006.  GPAQ information collected at Screening will be utilized to normali ze steps per day 
based on lifestyles activity.  GPAQ information will be a model covariate in subsequent 
analyses.  
9.4.4.  Safety Analyses  
AEs will be coded using the Medical Dictionary for Regulatory Activities (MedDRA ) dictionary.  
Incidences (number and percent) TEAEs, those events that started after dosing or worsened in 
severity after dosing, will be presented by [CONTACT_1570].  Incidences of TEAEs will also be 
presented by [CONTACT_651364]. Similar presentations will 
be provided for serious AEs, AEs leading to withdrawal from the study, or AEs leading to death.  
Analysis of AE data will include examination of the incidence rates  and changes in severity  of 
TEAEs and index knee r elated TEAEs following the first dose and second dose, as well as the 
cumulative incidence of TEAEs after all doses of FX006. Both the number of events and the 
number of patients experiencing an event will be examined to assess the by [CONTACT_651365] . The cumulative TEAE incidence rate 
will also be compared with total exposure to FX006.  
Clinical laboratory data and vital sign information will be presented as descriptive summary 
statistics for value  and change from Baseline at each individual time point.  
Flexion Therapeutics, Inc . Protocol FX006 -[ADDRESS_873476] the clinical study monitor during these visits.   
The Principal Investig ator will give the monitor, auditor(s), Sponsor, Sponsor designee and 
regulatory authorities direct access to relevant clinical records to confirm their consistency with 
the eCRF entries.  No information in these records about the identity of the patients will leave the 
clinical site.  The Sponsor will maintain the confidentiality of all patient records.  
Source data is all information in original records and certified copi[INVESTIGATOR_2149], observations, or other activities in a cl inical trial necessary for the 
reconstruction and evaluation of the trial.  Source data are contained in source documents 
(original records or certified copi[INVESTIGATOR_014]).  
Independent clinical quality assurance audits may be performed at any time during or following  
completion of the Study by [CONTACT_1034], or its authorized agents, and Competent Authorities 
and/or the IRB/EC.  
 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 51 of 57 
 11. DATA HANDLING AND RE CORDKEEPI[INVESTIGATOR_1645]  
11.1. Case Report Forms  
The eCRF will be supplied by [CONTACT_651366]. All study data should initially be documented in source documents 
(e.g., patient charts, notes, laboratory reports, ECG recordings, etc.) and then subsequently 
entered from the source into the eCRF.  All eCRFs  should be filled out completely by [CONTACT_538767].  The eCRF is reviewed, signed, and dated electronically by 
[CONTACT_079].  
11.2. Study Medication  Accountability  
All study medication  required for completion of this st udy will be provided by [CONTACT_95346] .  Study medication will be acknowledge d upon receipt indicating shipment content and 
condition.  Damaged supplies will be replaced.  
Accurate records of all study medications  received by, dispensed from, or returned by [CONTACT_651367] . 
In the event of a temperature excursion, refer to the Pharmacy Binder for instructions.  In the 
event of a product complaint, complete the Product Complaint Form located in the P harmacy 
Binder and send to  [EMAIL_12366] . The assigned monitor or 
clinical manager will coordinate with the Sponsor for further guidance.  
11.3. Confidentiality of Data  
Patient medical information obtained by [CONTACT_78793], and disclosure to third parties 
other than those noted below is prohibited.  
Upon the patient’s permission, medical information may be given to his or her personal 
physician or other approp riate medical personnel responsible for his or her welfare.  
Data generated by [CONTACT_538768], the Sponsor or their representative, and the IRB /EC. 
To maintain patient privacy, all eCR Fs, study drug accountability records, study reports, and 
communications will identify the patient by [CONTACT_175225]/or by [CONTACT_51266].  The patient’s confidentiality will be maintained and will not be made publicly 
available to the extent permitted by [CONTACT_4913].  
11.4. Retention of Records  
In accordance with US federal regulations (21 CFR 312.62[c]), the Sponsor requires that records 
and documents pertaining to the conduct of this study and the distribution of study medications , 
including eCRFs, consent forms, laboratory test results,  glucos e source data, and  medical 
inventory records, must be retained by [CONTACT_079] [INVESTIGATOR_8178] [ADDRESS_873477] be approved by [CONTACT_651368] /EC.  When the changes involved are only logistical and 
administrative in nature to trial this may not require prior approval by [CONTACT_1201] /EC. The Princi pal 
Investigator will be responsible for enrolling only those patients who have met protocol 
eligibility criteria.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 53 of 57 
 12. PUBLICATION  POLICY  
12.1. Sponsor’s Publication Policy  
Sponsor or its designee shall have the right to publish or otherwise publicly disclose the 
information contained in or related to the Study Drug, the Study Data, or other Confidential 
Information in any form without the written consent of Site, the Principal Investigator [INVESTIGATOR_538719].  Each of Site and Principal Investigator [INVESTIGATOR_651340] s that Sponsor shall have the 
exclusive right to commercialize any products or services that are based upon, or derived from 
the Study Drug, the Study Data, or other Confidential Information.  
12.2. Site Publication  
After the Study is completed, which means that all completed eCRFs have been received by 
[CONTACT_2728], and the database has been locked at all participating sites and Study closeout visits have 
taken place at all participating sites, then Site shall have the right, subject to the HIPAA Rules, to 
publish or otherwise make public data resulting from the conduct of the Study at the Site upon 
the earlier of (a)  the date of publication of a multi -center publication coordinated by [CONTACT_538770], and (b)  the date of submi ssion of the data 
resulting from the Study by [CONTACT_538771]; provided that Site shall 
furnish Sponsor with a copy of any proposed publication or release at least 90  days in advance of 
the proposed submission or presentation dat e.  Within this 90 -day period, the Sponsor shall 
review such proposed publication or release to determine whether it contains any Confidential 
Information (other than Study Data), or whether Sponsor desires to file patent applications on 
subject matter con tained therein, and to ensure the accuracy of the information contained in the 
publication or release. Upon receiving any notification from Sponsor requesting deletion of 
Confidential Information (other than Study Data), requesting correction of inaccuraci es, or 
requesting a delay in publication of up to 90  days to allow the filing of patent applications before 
publication or release, Site shall take the requested action.  The parties acknowledge and agree 
that Site shall be solely responsible for the edito rial content of any such publication or release.  
In a manner consistent with customary practice, Site shall acknowledge the support and 
contributions of Sponsor, if requested by [CONTACT_2728], in connection with the Study, in any and all 
publications and presen tations reporting and data resulting from the Study.  Site and the Principal 
Investigator [INVESTIGATOR_538721] (financial or otherwise) in connection with 
such publications and presentations.  
 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 54 of 57 
 13. REFERENCES  
Altman R, Asch E, Bloch D, Bole G, Borenstein D, Brandt K, et al. The American College of 
Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthriti s 
Rheum 1986;29:1039 -1049  
Ayral X, Pi[INVESTIGATOR_651341], Woodworth TG, Mackillop N, Dougados M. Synovitis: a potential 
predictive factor of structural progression of medial tibiofemoral knee osteoarthritis -- results of 
a 1 year longitudinal arthroscopic study in 422 patients. Osteoarthritis Cartilage 2005;13:[ADDRESS_873478] Rev. 
2006 Apr 19;(2):CD005328  
Benito MJ, Veale DJ, FitzGerald O, van den Berg WB, Bresnihan B.  Synovial tissue 
inflam mation in early and late osteoarthritis.  Ann Rheum Dis 2005;64:1263 -1267.  
Bodick N, Lufkin J, Willwerth C, Blanks R, Inderjeeth C, Kumar A, Clayman M.   FX006 
prolongs the residency of triamcinolone acetonide in the synovial tissues  of patients with knee 
osteoarthritis. Osteoarthritis Cartilage. 2013;21:(Suppl);  S144 -5. 
Bodick N, Lufkin J, Willwerth C, Kumar A, Bolognese J, Schoonmaker C, Ballal R, Hunter D, 
Clayman, M.  An Intra -Articular, Extended -Release Formulation of Triamcinolone Acetonide 
Prolongs an d Amplifies Analgesic Effect in Patients with Osteoarthritis of the Knee, A 
Randomized Clinical Trial. J Bone Joint Surg Am. 2015;97:877 -88 
Creamer P, Hochberg MC.  Osteoarthritis.   Lancet 1997;350(906):503 –508. 
Dworkin RH, Turk DC, Farrar JT, Haythornthw aite JA, Jensen MP, Katz NP, Kerns RD, Stucki 
G, Allen RR, Bellamy N, Carr DB, Chandler J, Cowan P, Dionne R, Galer BS, Hertz S, Jadad 
AR, Kramer LD, Manning DC, Martin S, McCormich CG, McDermott MP, McGrath P, Quessy 
S, Rappaport BA, Robbins W, Robinson J P, Rothman M, Royal MA, Simon L, Stauffer JW, 
Stein W, Tollet J, Wernicke J, Witter J.  Core outcome measures for chronic pain clinical trials: 
IMMPACT recommendations.  Pain 2005; 113:[ADDRESS_873479] 2006;6(4):376 –378. 
Habib GS.  Systemic effects of intra -articular corticosteroids. Clin Rheumatol 2009;28:749 –756. 
Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, Towheed T, Welch 
V, Wells G, Tugwell P.  American College of Rheumatology 2012 Recommendations for the 
Use of Nonpharmacologic and Pharmacologic Therapi[INVESTIGATOR_651342] s of the Hand, Hip, and 
Knee.  Arthritis Care & Research 2012; 64:465 -474. 
Jordan KM, Arden N K, Doherty M, Bannwarth B, Bijlsma JW, Dieppe P, Gunther K, 
Hauselmann H, Herrero -Beaumont, Kaklamanis P, Lohmander S, Leeb B, Lequesne M, 
Mazieres B, Martin -Mola E, Pavelka K, Pendleton A, Punzi L, Serni U, Swoboda B, Verbruggen 
G, Zimmerman -Gorska I, Dou gados M.  EULAR Recommendations 2003: an evidence based 
approach to the management of knee osteoarthritis: Report of a Task Force of the Standing 
Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT).  Ann 
Rheum Dis 2003;62(12 ):1145 –1155.  
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 55 of 57 
 Sellam J and Berenbaum F.  The role of synovitis in pathophysiology and clinical symptoms of 
osteoarthritis.  Nature Reviews Rheumatology  2010;6:625 -635. 
Wenham CYJ and Conaghan PG.  The role of synovitis in osteoarthritis.  Ther Adv Musculos kel 
Dis  2010;2:349 -359. 
 
 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 56 of 57 
 14. APPENDI CES  
APPENDIX  1. KNEE OA DIAGNOSIS AS SESSMENTS  
American College of Rheumatology Criteria for Classification of Idiopathic OA of the 
Knee  (Altman et al, 1986 ) 
Clinical and radiological  
 Knee Pain  
 + at least 1 of 3:  
o Age > 50 years  
o Stiffness < 30 minutes  
o Crepi[INVESTIGATOR_72831]  
 + Osteophytes  
Kellgren -Lawrence Grade of Knee X -ray  
 
 Grade 0: no findings  
 Grade 1: doubtful narrowing of joint pace and possible osteophytic lippi[INVESTIGATOR_007]  
 Grade 2: definite osteophytes and possib le narrowing of joint space  
 Grade 3: moderate multiple osteophytes, definite narrowing of joint space and some 
sclerosis and possible deformity of bone ends  
 Grade 4: large osteophytes, marked narrowing of joint space, severe sclerosis and definite 
deformit y of bone ends  
 
 
 
 
 
Flexion Therapeutics, Inc . Protocol FX006 -2016 -011 
FX006  Version 2.0 16 October 2017  
  
CONFIDENTIAL   Page 57 of 57 
 APPENDIX  2. STUDY VISIT FLOW CHA RT 
 
 
 
